[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1204656A1 - Methods and compositions involving mirna and mirna inhibitor molecules mirna mirna - Google Patents

Methods and compositions involving mirna and mirna inhibitor molecules mirna mirna

Info

Publication number
HK1204656A1
HK1204656A1 HK15105287.4A HK15105287A HK1204656A1 HK 1204656 A1 HK1204656 A1 HK 1204656A1 HK 15105287 A HK15105287 A HK 15105287A HK 1204656 A1 HK1204656 A1 HK 1204656A1
Authority
HK
Hong Kong
Prior art keywords
mirna
methods
inhibitor molecules
compositions involving
compositions
Prior art date
Application number
HK15105287.4A
Other languages
English (en)
Chinese (zh)
Inventor
David Brown
Lance Ford
Angie Cheng
Rich Jarvis
Mike Byrom
Dmitriy Ovcharenko
Eric Devroe
Kevin Kelnar
Original Assignee
Asuragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37570916&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1204656(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asuragen Inc filed Critical Asuragen Inc
Publication of HK1204656A1 publication Critical patent/HK1204656A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3527—Other alkyl chain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3535—Nitrogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/533—Physical structure partially self-complementary or closed having a mismatch or nick in at least one of the strands
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
HK15105287.4A 2004-11-12 2015-06-03 Methods and compositions involving mirna and mirna inhibitor molecules mirna mirna HK1204656A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62717104P 2004-11-12 2004-11-12
US64963405P 2005-02-03 2005-02-03
US68373605P 2005-05-23 2005-05-23

Publications (1)

Publication Number Publication Date
HK1204656A1 true HK1204656A1 (en) 2015-11-27

Family

ID=37570916

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105287.4A HK1204656A1 (en) 2004-11-12 2015-06-03 Methods and compositions involving mirna and mirna inhibitor molecules mirna mirna

Country Status (11)

Country Link
US (25) US8173611B2 (es)
EP (21) EP2302052B1 (es)
JP (11) JP2008519606A (es)
AU (1) AU2005333165B2 (es)
CA (7) CA2857880A1 (es)
DK (1) DK2302055T3 (es)
ES (13) ES2534302T3 (es)
HK (1) HK1204656A1 (es)
PL (1) PL2302055T3 (es)
SI (1) SI2302055T1 (es)
WO (1) WO2006137941A2 (es)

Families Citing this family (391)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2385122B1 (en) 2001-09-28 2018-04-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
EP2065466B1 (en) * 2004-05-28 2014-07-09 Asuragen, Inc. Methods and compositions involving MicroRNA
WO2006027776A1 (en) * 2004-09-07 2006-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
US20090186353A1 (en) * 2004-10-04 2009-07-23 Rosetta Genomics Ltd. Cancer-related nucleic acids
US7642348B2 (en) * 2004-10-04 2010-01-05 Rosetta Genomics Ltd Prostate cancer-related nucleic acids
US7825229B2 (en) * 2005-03-25 2010-11-02 Rosetta Genomics Ltd. Lung cancer-related nucleic acids
EP2302052B1 (en) 2004-11-12 2015-01-07 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
EP1877557A2 (en) 2005-04-04 2008-01-16 The Board of Regents of The University of Texas System Micro-rna's that regulate muscle cells
EP2631294A3 (en) * 2005-04-29 2013-11-20 The Rockefeller University Human microRNAs and methods for inhibiting same
EP1904111A4 (en) * 2005-06-03 2009-08-19 Univ Johns Hopkins COMPOSITIONS AND METHODS FOR REDUCING MICRORNA EXPRESSION FOR THE TREATMENT OF NEOPLASIA
CA2617581A1 (en) * 2005-08-01 2007-02-08 The Ohio State University Research Foundation Microrna-based methods for the diagnosis of breast cancer
WO2007033023A2 (en) 2005-09-12 2007-03-22 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of bcl2-associated cancers
JP2009511482A (ja) * 2005-10-05 2009-03-19 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション Ｗｗｏｘ遺伝子、同じものを含むベクター、および癌の治療における使用
EP2671949A1 (en) 2005-12-12 2013-12-11 University Of North Carolina At Chapel Hill Micro-RNA miR-145 that regulate muscle cell proliferation and differentiation
CN103361424A (zh) 2006-01-05 2013-10-23 俄亥俄州立大学研究基金会 胰腺内分泌和腺泡肿瘤中的微小rna表达异常
AU2016203848B2 (en) * 2006-01-05 2017-12-14 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
AU2007205234B2 (en) 2006-01-05 2012-07-12 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
EP2468894B1 (en) * 2006-01-05 2014-12-10 The Ohio State University Research Foundation MicroRNA-based Methods and Compositions for the Diagnosis of Breast Cancer
JP5523825B2 (ja) * 2006-03-20 2014-06-18 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション ヒト巨核球形成間のマイクロｒｎａフィンガープリント
NZ571569A (en) 2006-04-03 2011-09-30 Santaris Pharma As Pharmaceutical compositions comprising anti miRNA antisense oligonucleotides
KR101407707B1 (ko) 2006-04-03 2014-06-19 산타리스 팔마 에이/에스 Ａｎｔｉ-ｍｉｒｎａ 안티센스 올리고뉴클레오타이드를 함유하는 약학적 조성물
ES2425387T3 (es) 2006-07-13 2013-10-15 The Ohio State University Research Foundation Mir-106a para diagnosticar adenocarcinoma de colon de pronóstico de supervivencia pobre
CA2659364C (en) 2006-08-01 2017-08-22 Board Of Regents Of The University Of Texas System Identification of a micro-rna that activates expression of .beta.-myosin heavy chain
AU2007280004A1 (en) † 2006-08-04 2008-02-07 Dublin City University A method of producing recombinant biological products
US8673872B2 (en) * 2006-08-28 2014-03-18 The University Of Western Australia Method of modulation of expression of epidermal growth factor receptor(EGFR) involving miRNA
JPWO2008029790A1 (ja) * 2006-09-04 2010-01-21 協和発酵キリン株式会社 新規核酸
WO2008036776A2 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
EP2061907B1 (en) 2006-09-19 2011-11-23 The Ohio State University Research Foundation Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181
WO2008057234A2 (en) * 2006-10-24 2008-05-15 The Board Of Trustees Of The Leland Stanford Junior University Modulation of t cell signaling threshold and t cell sensitivity to antigens
JP5501766B2 (ja) 2006-11-01 2014-05-28 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 肝細胞癌における生存および転移を予測するためのマイクロｒｎａ発現サイン
US20080131878A1 (en) * 2006-12-05 2008-06-05 Asuragen, Inc. Compositions and Methods for the Detection of Small RNA
CN101622349A (zh) * 2006-12-08 2010-01-06 奥斯瑞根公司 作为治疗性干预靶标的miR-21调节的基因和途径
CA2671194A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-20 regulated genes and pathways as targets for therapeutic intervention
CA2671299A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Functions and targets of let-7 micro rnas
CA2671294A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
CA2671296A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-126 regulated genes and pathways as targets for therapeutic intervention
CA2671270A1 (en) * 2006-12-29 2008-07-17 Asuragen, Inc. Mir-16 regulated genes and pathways as targets for therapeutic intervention
EP2111408A4 (en) * 2007-01-17 2010-02-03 Univ Johns Hopkins COMPOSITIONS AND METHODS OF microRNA FOR THE TREATMENT OF NEOPLASIA
AU2008211142A1 (en) 2007-01-31 2008-08-07 The Ohio State University Research Foundation Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
US9006206B2 (en) 2007-02-27 2015-04-14 Rosetta Genomics Ltd. Composition and methods for modulating cell proliferation and cell death
AU2008220438A1 (en) 2007-02-27 2008-09-04 Rosetta Genomics Ltd. Composition and methods for modulating cell proliferation and cell death
EP2134842A2 (en) * 2007-03-07 2009-12-23 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
WO2008115387A2 (en) * 2007-03-15 2008-09-25 University Hospitals Of Cleveland Screening, diagnosing, treating and prognosis of pathophysiologic states by rna regulation
EP2136846A4 (en) * 2007-03-26 2011-04-13 Crc For Asthma And Airways Ltd THERAPEUTIC OBJECTIVES AND MOLECULES
US20100273172A1 (en) * 2007-03-27 2010-10-28 Rosetta Genomics Ltd. Micrornas expression signature for determination of tumors origin
US20090117562A1 (en) 2007-04-09 2009-05-07 Valerie Wailin Hu Method and kit for diagnosing Autism using gene expression profiling
CN101827941B (zh) * 2007-04-30 2014-07-16 俄亥俄州立大学研究基金会 用于区分胰腺癌与正常胰腺功能和/或慢性胰腺炎的方法
EP1990414A1 (en) * 2007-05-10 2008-11-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Means for treating inflammatory diseases, autoimmune diseases and cancer
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
WO2008147974A1 (en) * 2007-05-23 2008-12-04 University Of South Florida Micro-rnas modulating immunity and inflammation
CN101711287B (zh) * 2007-06-08 2016-04-27 由卫生与公众服务部代表的美利坚合众国政府 确定肝细胞癌亚型和检测肝癌干细胞的方法
CN101801419A (zh) * 2007-06-08 2010-08-11 米尔纳疗法公司 作为治疗干预的靶标的miR-34调控的基因和路径
CA2690749A1 (en) 2007-06-15 2008-12-24 The Ohio State University Research Foundation Oncogenic all-1 fusion proteins for targeting drosha-mediated microrna processing
WO2009006577A2 (en) * 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
DK2182969T3 (en) 2007-07-31 2017-02-27 Univ Texas Micro-RNA family that modulates fibrosis and its applications
AU2008283794B2 (en) 2007-07-31 2014-03-20 Board Of Regents, The University Of Texas System Micro-RNAs that control myosin expression and myofiber identity
JP2010535782A (ja) 2007-07-31 2010-11-25 ズィ、オハイオウ、ステイト、ユーニヴァーサティ、リサーチ、ファウンデイシャン Ｄｎｍｔ３ａ及びｄｎｍｔ３ｂを標的にすることによるメチル化を元に戻す方法
WO2009017803A2 (en) * 2007-08-02 2009-02-05 The Texas A & M University System Antisense microrna and uses therefor
CN101835902B (zh) 2007-08-03 2014-03-26 俄亥俄州立大学研究基金会 编码ncrna的超保守区域
US20120070442A1 (en) * 2007-08-09 2012-03-22 The Regents Of The University Of Colorado, A Body Corporate Methods and compositions for treating cancer
US8716255B2 (en) 2007-08-10 2014-05-06 British Columbia Cancer Agency Branch Microrna compositions and methods for the treatment of myelogenous leukemia
AU2008288806B2 (en) 2007-08-22 2014-11-27 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of EphA7 and Erk phosphorylation in human acute leukemias
CN101376910B (zh) * 2007-08-27 2012-01-11 中国科学院上海生命科学研究院 微小rna基因在系统性红斑狼疮疾病诊断和治疗中的作用
EP3048177A1 (en) * 2007-09-06 2016-07-27 The Ohio State University Research Foundation Microrna signatures in human ovarian cancer
EP2198050A1 (en) 2007-09-14 2010-06-23 Asuragen, INC. Micrornas differentially expressed in cervical cancer and uses thereof
WO2009044895A1 (ja) * 2007-10-03 2009-04-09 Kyowa Hakko Kirin Co., Ltd. 標的遺伝子の発現を抑制する組成物
US20100305188A1 (en) * 2007-10-03 2010-12-02 Kyowa Hakko Kirin Co., Ltd. Nucleic acid capable of regulating the proliferation of cell
MY156951A (en) 2007-10-04 2016-04-15 Santaris Pharma As Micromirs
WO2009049129A1 (en) * 2007-10-11 2009-04-16 The Ohio State University Research Foundation Methods and compositions for the diagnosis and treatment of esphageal adenocarcinomas
WO2009052386A1 (en) * 2007-10-18 2009-04-23 Asuragen, Inc. Micrornas differentially expressed in lung diseases and uses thereof
CN103898069A (zh) 2007-10-26 2014-07-02 俄亥俄州立大学研究基金会 鉴定脆性组氨酸三联体(Fhit)相互作用的方法及其用途
WO2009058907A2 (en) 2007-10-29 2009-05-07 Isis Pharmaceuticals, Inc. Targeting micrornas for the treatment of liver cancer
AU2008324814B2 (en) * 2007-11-05 2013-05-16 Solventum Intellectual Properties Company Identification of tissue for debridement
MX2010005166A (es) * 2007-11-09 2010-10-07 Univ Texas Micro arn de la familia mir-15 que modulan la sobrevivencia de cardiomiocitos y reparacion cardiaca.
ITRM20070595A1 (it) * 2007-11-15 2009-05-16 Univ Roma Mirna e sirna e loro uso in terapia
EP2520649A3 (en) * 2007-11-23 2013-02-20 Panagene, Inc. MicroRNA antisense PNAs, compositions comprising the same, and methods for using and evaluating the same
WO2009070653A1 (en) * 2007-11-30 2009-06-04 The Ohio State University Research Foundation Microrna expression profiling and targeting in peripheral blood in lung cancer
WO2009070805A2 (en) * 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
WO2009086156A2 (en) * 2007-12-21 2009-07-09 Asuragen, Inc. Mir-10 regulated genes and pathways as targets for therapeutic intervention
KR101325186B1 (ko) 2008-01-23 2013-11-07 (주)바이오니아 이중가닥 ｍｉＲＮＡ를 유효성분으로 포함하는 항암제
JP5116026B2 (ja) 2008-01-23 2013-01-09 富士フイルム株式会社 癌の検出方法および癌抑制剤
EP2234483A4 (en) 2008-01-27 2011-04-27 Rosetta Genomics Ltd METHOD AND COMPOSITIONS FOR DIAGNOSIS OF PREGNANCY COMPLICATIONS
WO2009100430A2 (en) * 2008-02-08 2009-08-13 Asuragen, Inc miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
ES2600165T3 (es) * 2008-02-28 2017-02-07 The Ohio State University Research Foundation Antagonistas de miR-32 para aumentar la respuesta del cáncer de próstata a la apoptosis
US20110052502A1 (en) * 2008-02-28 2011-03-03 The Ohio State University Research Foundation MicroRNA Signatures Associated with Human Chronic Lymphocytic Leukemia (CCL) and Uses Thereof
US20110034538A1 (en) * 2008-02-28 2011-02-10 The Ohio State University Research Foundation MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Gastric Cancer
WO2009109665A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
US8202848B2 (en) 2008-03-17 2012-06-19 Board Of Regents, The University Of Texas System Identification of micro-RNAS involved in neuromuscular synapse maintenance and regeneration
AU2009228393B2 (en) * 2008-03-24 2014-10-02 New York University Compositions and methods for diagnosing and treating melanoma
WO2009154835A2 (en) * 2008-03-26 2009-12-23 Asuragen, Inc. Compositions and methods related to mir-16 and therapy of prostate cancer
WO2009121031A1 (en) * 2008-03-27 2009-10-01 Vascular Biosciences, Inc. Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases
US9179654B2 (en) * 2008-04-07 2015-11-10 Cornell Research Foundation, Inc. Inhibition of angiogenesis
US20090258928A1 (en) * 2008-04-08 2009-10-15 Asuragen, Inc. Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
CN102076853A (zh) * 2008-05-07 2011-05-25 阿布拉西斯生物科学有限责任公司 通过miRNA增强药物疗法
WO2009137807A2 (en) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
US20110178159A1 (en) * 2008-05-08 2011-07-21 Hua Gu Inhibitory rnas that regulate hematopoietic cells
WO2009147658A2 (en) * 2008-06-02 2009-12-10 New York University Compositions and methods for diagnosis, prognosis and treatment of mesothelioma
EP2300017A4 (en) * 2008-06-05 2012-12-12 Univ New York State Res Found ARNMI AS THERAPEUTIC TARGETS IN CANCER
CN102112110A (zh) * 2008-06-06 2011-06-29 米尔纳医疗股份有限公司 用于RNAi试剂体内递送的新型组合物
US8247388B2 (en) * 2008-06-06 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Role of miRNA in T cell leukemia
CA2727633A1 (en) 2008-06-11 2009-12-17 Xin W. Wang Use of mir-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy
US8252534B2 (en) * 2008-06-12 2012-08-28 City Of Hope Micro RNAs and their methods of use for the treatment and diagnosis of schizophrenia and schizophrenia spectrum disorders
US20110077168A1 (en) * 2008-06-17 2011-03-31 Nitzan Rosenfeld Methods for distinguishing between specific types of lung cancers
US9540695B2 (en) 2008-06-17 2017-01-10 Rosetta Genomics Ltd. Compositions and methods for prognosis of ovarian cancer
PL2297357T3 (pl) 2008-06-27 2013-03-29 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Res Przewidywanie odpowiedzi na leczenie przeciwwirusowe
CA2729713C (en) * 2008-07-01 2020-07-28 Monsanto Technology Llc Recombinant dna constructs and methods for modulating expression of a target gene
US20110117567A1 (en) * 2008-07-03 2011-05-19 National University Corporation Kobe University Micro-RNA Associated With Rheumatoid Arthritis
WO2010012667A1 (en) 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
KR101042052B1 (ko) * 2008-08-05 2011-06-16 사회복지법인 삼성생명공익재단 항-ｍｉｃｒｏＲＮＡ를 포함하는 고형암 예방 또는 치료용조성물
WO2010017551A2 (en) * 2008-08-08 2010-02-11 The General Hospital Corporation Method for mir-125a in promoting hematopoietic stem cell self renewal and expansion
WO2010019446A1 (en) * 2008-08-09 2010-02-18 University Of Iowa Research Foundation Nucleic acid aptamers
US20110196017A1 (en) * 2008-08-11 2011-08-11 Olson Eric N Micro-rna that promotes vascular integrity and uses thereof
JP2012500389A (ja) * 2008-08-12 2012-01-05 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 多発性脊髄腫の診断、予後および治療のためのマイクロｒｎａに基づく組成物および方法
WO2010019874A1 (en) * 2008-08-15 2010-02-18 The Translational Genomics Research Institute (Tgen) Methods of predicting the risk of recurrence of cancer
US8557786B2 (en) * 2008-08-19 2013-10-15 Maine Institute of Human Genetics and Health Micro RNA (MiRNA) and neurofibromatosis type 1: a role in diagnosis and therapy
US9347089B2 (en) 2008-09-19 2016-05-24 Children's Medical Center Corporation Therapeutic and diagnostic strategies
EP3211098B1 (en) * 2008-11-10 2023-03-15 Battelle Memorial Institute Method utilizing microrna to determine physiological conditions
WO2010056737A2 (en) * 2008-11-11 2010-05-20 Mirna Therapeutics, Inc. Methods and compositions involving mirnas in cancer stem cells
US8734759B2 (en) * 2008-12-05 2014-05-27 Yeda Research And Development Co. Ltd. Methods of diagnosing and treating motor neuron diseases
US20120041048A1 (en) * 2008-12-05 2012-02-16 Whitehead Institute For Biomedical Research COMPOSITIONS AND METHODS RELATING TO miR-31
EP2208785A1 (en) 2009-01-15 2010-07-21 Newbiotechnic, S.A. Methods and kits to generate miRNA- and smallRNA-expressing vectors, and its application to develop lentiviral expression libraries
US8492133B2 (en) 2009-01-20 2013-07-23 Ramot At Tel Aviv University, Ltd. MIR-21 promoter driven targeted cancer therapy
AU2010207975B2 (en) 2009-02-02 2016-04-28 Cepheid Methods of detecting sepsis
KR20110128838A (ko) 2009-02-04 2011-11-30 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 심장 질환 치료에서 ｍｉｒ－208 및 ｍｉｒ－499의 이중 표적화
EP2218458A1 (en) * 2009-02-13 2010-08-18 Fondazione Telethon Molecules able to modulate the expression of at least a gene involved in degradative pathways and uses thereof
US20100311815A1 (en) * 2009-02-23 2010-12-09 The Regents Of The University Of Michigan Mir-101 cancer markers
WO2010099161A1 (en) * 2009-02-26 2010-09-02 The Ohio State University Research Foundation Micrornas in never-smokers and related materials and methods
WO2010107397A1 (en) * 2009-03-19 2010-09-23 Agency For Science, Technology And Research Modulators of apoptosis and the uses thereof
US20120087992A1 (en) * 2009-03-20 2012-04-12 Jingfang Ju miRNAS AS THERAPEUTIC TARGETS IN CANCER
JP2012522508A (ja) 2009-03-31 2012-09-27 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ シェーグレン症候群の診断および治療のためのバイオマーカーとしての示差的に発現されるマイクロｒｎａ
WO2010120969A1 (en) * 2009-04-15 2010-10-21 Board Of Regents, The University Of Texas System Targeting of the mir-30 family and let-7 family as a treatment for heart disease
US9034837B2 (en) 2009-04-24 2015-05-19 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon
KR101758667B1 (ko) 2009-04-29 2017-07-18 아카데미쉬 메디쉬 센트륨 심부전 또는 심부전 위험성을 방지, 예방 및/또는 측정하기 위한 수단 및 방법
US9085798B2 (en) 2009-04-30 2015-07-21 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
WO2010129919A1 (en) * 2009-05-08 2010-11-11 Research Development Foundation Mirna expression in allergic disease
WO2010129860A2 (en) * 2009-05-08 2010-11-11 The Ohio State University Research Foundation Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof
WO2010131162A2 (en) * 2009-05-11 2010-11-18 Koninklijke Philips Electronics N.V. Device and method for comparing molecular signatures
MX2011012418A (es) 2009-05-20 2012-07-20 Univ Texas Identificacion de micro-arns implicados en la remodelacion posterior al infarto de miocardio y en la insuficiencia cardiaca.
EP2432880A1 (en) 2009-05-20 2012-03-28 ETH Zürich Targeting micrornas for metabolic disorders
WO2010136417A1 (en) * 2009-05-25 2010-12-02 Università Degli Studi Di Roma "La Sapienza" miR-31 IN DUCHENNE MUSCULAR DYSTROPHY THERAPY
CA2762303A1 (en) * 2009-05-25 2010-12-02 Carola Ponzetto Differentiation therapy for sarcomas
MX2011013337A (es) 2009-06-10 2012-06-19 Brainstem Biotec Ltd Metodos, sistemas y composiciones para la diferenciacion neuronal de celulas estromales multipotentes.
US20100322909A1 (en) 2009-06-17 2010-12-23 The University Of Pittsburgh - Of The Commonwealth System Of Higher Education Th1-associated micrornas and their use for tumor immunotherapy
WO2010151755A2 (en) * 2009-06-25 2010-12-29 The Brigham And Women's Hospital, Inc. TREATMENT OF INFLAMMATORY DISEASES USING miR-124
WO2011012136A1 (en) * 2009-07-28 2011-02-03 Exiqon A/S A method for classifying a human cell sample as cancerous
FR2948687B1 (fr) * 2009-07-29 2015-09-04 Centre Nat Rech Scient Utilisation de microarn pour le traitement de pathologies respiratoires chroniques
US8911940B2 (en) 2009-07-31 2014-12-16 The Translational Genomics Research Institute Methods of assessing a risk of cancer progression
WO2011017516A2 (en) * 2009-08-05 2011-02-10 Curna, Inc. Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
WO2011017408A1 (en) * 2009-08-05 2011-02-10 The Ohio State University Research Foundation Anti-mir-1 therapy for wound healing
EP2283846A1 (en) 2009-08-12 2011-02-16 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. miRNA compounds for treatment of prostate carcinoma
US8796238B2 (en) 2009-09-17 2014-08-05 Sigma-Aldrich Co. Llc Short RNA mimetics
US20130065949A1 (en) * 2009-10-14 2013-03-14 Baylor College Of Medicine Microrna mirna-31 as a therapeutic approach for the treatment of cancer
WO2011059752A1 (en) * 2009-10-28 2011-05-19 Board Of Regents Of The University Of Texas System Methods and compositions for anti-egfr treatment
EP3118334A1 (en) 2009-11-04 2017-01-18 DiamiR, LLC Methods of using small rna from bodily fluids for diagnosis and monitoring of neurodegenerative diseases
AU2010321555B2 (en) 2009-11-23 2015-10-15 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
WO2011063455A1 (en) * 2009-11-24 2011-06-03 The University Of Western Australia Modulation of epidermal growth factor receptor ligands
EP2327783A1 (en) * 2009-11-27 2011-06-01 Universitätsklinikum Freiburg Pharmaceutical composition comprising miRNA-100 and its use in the modulation of blood vessel growth
US8354520B2 (en) * 2009-12-10 2013-01-15 Kaohsiung Medical University Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug
JP5804459B2 (ja) * 2009-12-21 2015-11-04 国立大学法人広島大学 癌疾患用細胞老化促進剤
WO2011084815A1 (en) * 2009-12-21 2011-07-14 Board Of Trustees Of Southern Illinois University Inhibition of ubc9-mediated cancer cell invasion and metastasis
US20120315640A1 (en) 2009-12-21 2012-12-13 Hidetoshi Tahara Senescence marker, method for evaluating senescence inhibitor, and cancer inhibitor
US20130012403A1 (en) * 2009-12-23 2013-01-10 George Washington University Compositions and Methods for Identifying Autism Spectrum Disorders
EP2341145A1 (en) * 2009-12-30 2011-07-06 febit holding GmbH miRNA fingerprint in the diagnosis of diseases
WO2011088309A1 (en) 2010-01-14 2011-07-21 Regulus Therapeutics Inc. Microrna compositions and methods
WO2011091209A1 (en) * 2010-01-21 2011-07-28 North Carolina State University Small molecule modifiers of microrna mir-122
JP2011188849A (ja) * 2010-02-18 2011-09-29 Okayama Univ 抗腫瘍効果を有するｍｉＲ−７発現プラスミド
US8841269B2 (en) * 2010-02-23 2014-09-23 Creighton University Polynucleotides for use in treating and diagnosing cancers
EP3214174B1 (en) * 2010-03-04 2019-10-16 InteRNA Technologies B.V. A mirna molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with emt
WO2011111715A1 (ja) * 2010-03-09 2011-09-15 協和発酵キリン株式会社 細胞周期を制御する核酸
AU2011237729B2 (en) 2010-04-05 2014-04-03 Prognosys Biosciences, Inc. Spatially encoded biological assays
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
CA2795815C (en) 2010-04-23 2018-06-26 Cold Spring Harbor Laboratory Novel structurally designed shrnas
WO2011150420A1 (en) * 2010-05-28 2011-12-01 Baylor College Of Medicine Modified gold nanoparticles for therapy
WO2011153542A2 (en) 2010-06-04 2011-12-08 Board Of Regents, The University Of Texas System Regulation of metabolism by mir-378
ES2526897T3 (es) * 2010-06-09 2015-01-16 Chanel Parfums Beauté Inhibidores de varios microARN para usar en la prevención y/o atenuación del envejecimiento cutáneo y/o para hidratar la piel
WO2012005572A1 (en) * 2010-07-06 2012-01-12 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
EP2594643B1 (en) * 2010-07-12 2017-04-12 National University Corporation Tottori University Method for producing novel hipsc by means of sirna introduction
US8580513B2 (en) * 2010-07-20 2013-11-12 Trustees Of Dartmouth College Methods for determining response to neoadjuvant therapy and survival using MicroRNA-10b
WO2012012716A2 (en) 2010-07-23 2012-01-26 Regulus Therapeutics, Inc. Targeting micrornas for the treatment of fibrosis
WO2012023132A1 (en) * 2010-08-16 2012-02-23 Brainstem Biotech Ltd. Methods of generating oligodendrocytes and cell populations comprising same
US10385314B2 (en) 2010-08-16 2019-08-20 Exostem Biotec Ltd. Methods of generating oligodendrocytes and cell populations comprising same
AU2011292809B2 (en) 2010-08-17 2017-04-13 Hopitaux Universitaires De Geneve BARD1 isoforms in lung and colorectal cancer and use thereof
US8642342B2 (en) 2010-08-19 2014-02-04 Regents Of The University Of Michigan Methods for regulating neural differentiation
EP2426217A1 (en) * 2010-09-03 2012-03-07 Centre National de la Recherche Scientifique (CNRS) Analytical methods for cell free nucleic acids and applications
US9006195B2 (en) * 2010-09-13 2015-04-14 California Institute Of Technology Regulation of hematopoietic stem cell functions through microRNAs
WO2012044265A1 (en) * 2010-09-27 2012-04-05 Sabanci Universitesi Use of mirnas for the diagnosis, prophylaxis, treatment and follow-up of diseases involving macroautophagy abnormalities
WO2012041959A1 (en) 2010-09-30 2012-04-05 University Of Zurich Treatment of b-cell lymphoma with microrna
JP5931897B2 (ja) * 2010-11-12 2016-06-08 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションＴｈｅ Ｏｈｉｏ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ マイクロｒｎａ−２１、ミスマッチ修復および結腸直腸癌に関連する物質および方法
JPWO2012063894A1 (ja) * 2010-11-12 2014-05-12 国立大学法人愛媛大学 マイクロｒｎａのアンチセンスオリゴヌクレオチドを含む組成物
EP2640368B1 (en) 2010-11-15 2020-12-30 The Ohio State University Research Foundation Controlled release mucoadhesive systems
AU2011329772B2 (en) 2010-11-17 2017-05-04 Interpace Diagnostics, Llc miRNAs as biomarkers for distinguishing benign from malignant thyroid neoplasms
US11344505B1 (en) 2010-12-01 2022-05-31 Gowey Research Group, Pllc Herbal formulations of carnivorous plants and methods for treating inflammation
WO2012072750A1 (en) * 2010-12-01 2012-06-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the outcome of colon cancer by analysing mirna expression
US10758578B2 (en) 2010-12-01 2020-09-01 Gowey Research Group PLLC Herbal formulations of carnivorous plants and methods for treating inflammation
US10744151B1 (en) * 2010-12-01 2020-08-18 Gowey Research Group PLLC Micro-RNA profiling, compositions, and methods of treating diseases
US11414663B2 (en) 2010-12-01 2022-08-16 Gowey Research Group, Pllc Micro-RNA profiling, compositions, and methods of treating diseases
WO2012082821A2 (en) * 2010-12-15 2012-06-21 Medimmune, Llc Melanoma treatments
AR084319A1 (es) 2010-12-15 2013-05-08 Miragen Therapeutics INHIBIDORES DE microARN (miARN O miR) QUE COMPRENDEN NUCLEOTIDOS BLOQUEADOS
EP2654801B1 (en) 2010-12-20 2017-11-01 Agency For Science, Technology And Research Targeting glioma stem cells by sequence-specific functional inhibition of pro-survival oncomir-138
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
CA2826043A1 (en) 2011-02-03 2012-08-09 Mirna Therapeutics, Inc. Synthetic mimics of mir-124
RU2615117C2 (ru) 2011-02-03 2017-04-04 Мирна Терапетикс, Инк. ДВУХЦЕПОЧЕЧНАЯ МОЛЕКУЛА РНК ДЛЯ ОБЕСПЕЧЕНИЯ КЛЕТКИ АКТИВНОСТЬЮ miR-34a
RS59161B1 (sr) * 2011-02-07 2019-10-31 Gabriella Sozzi Mikro-rnk biomarkeri za identifikovanje rizika i/ili dijagnostikovanje tumora pluća
WO2012122239A1 (en) 2011-03-07 2012-09-13 The Ohio State University MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (miR-155) LINKS INFLAMMATION AND CANCER
US9353370B2 (en) * 2011-03-30 2016-05-31 Riken Functional nucleic acid molecule and use thereof
EP2691548B1 (en) * 2011-03-31 2017-11-22 University of Houston Microrna 130a,b as a tumor suppressor and sensitizing agent for chemotherapy
WO2012140234A1 (en) 2011-04-13 2012-10-18 Vib Vzw Modulation of mirna in diseases with aberrant angiogenesis
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
RU2626540C2 (ru) 2011-04-18 2017-07-28 Диамир, Ллс Способы обнаружения патологических изменений в органе или системе органов
US8765707B2 (en) 2011-04-22 2014-07-01 University Of Houston System MicroRNA-140-5p as a tumor suppressor and sensitizing agent for chemotherapy
EP3933040A1 (en) 2011-04-25 2022-01-05 Sanofi Microrna compounds and methods for modulating mir-21 activity
EE201100037A (et) * 2011-05-16 2012-12-17 Tartu Ülikool MikroRNAde kasutamine biomarkeritena ja sihtm„rkidena raku proliferatiivsete omaduste m?jutamiseks ja meetod ning komplekt nende ekspressioonitaseme tuvastamiseks
CA2840405A1 (en) * 2011-06-27 2013-01-03 Galderma Research & Development New th17 differentiation markers for acne and uses thereof
US20140235475A1 (en) 2011-06-27 2014-08-21 Isabelle Carlavan Th17 differentiation markers for acne and uses thereof
US8747860B2 (en) 2011-07-06 2014-06-10 Institute For Systems Biology Methods and compositions to modulate antiviral and immune activity responses
WO2013019259A1 (en) 2011-08-01 2013-02-07 Thomson Licensing Telepresence communications system and method
ES2732427T3 (es) 2011-08-04 2019-11-22 Yeda Res & Dev Micro-ARN MIR-15 y composiciones que lo comprenden para el tratamiento de enfermedades asociadas con la hormona liberadora de corticotropina
US8987224B2 (en) 2011-08-05 2015-03-24 Baylor College Of Medicine MicroRNA-198 as a tumor suppressor in pancreatic cancer
WO2013023982A1 (en) 2011-08-12 2013-02-21 Westfaelische Wilhelms-Universitaet Muenster Novel compounds for the treatment of inflammatory bowel disease
WO2013032962A2 (en) * 2011-08-28 2013-03-07 The Board Of Trustees Of The Leland Stanford Junior University Micro rnas to treat stroke, ischemic brain injury, traumatic brain injury, and neurodegenerative disease
EP2751271A1 (en) * 2011-08-31 2014-07-09 Universität Zürich Prorektorat MNW Modulators of mir-323-3p for the prevention or treatment of rheumatoid arthritis
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
WO2013037065A1 (en) 2011-09-13 2013-03-21 Ottawa Hospital Research Institute Microrna inhibitors
JP6177243B2 (ja) 2011-10-06 2017-08-09 ミラゲン セラピューティクス， インコーポレイテッド マイクロｒｎａの調節による全身エネルギーホメオスタシスの制御
JP2014530612A (ja) 2011-10-14 2014-11-20 ジ・オハイオ・ステート・ユニバーシティ 卵巣がんに関する方法および材料
EP2584040A1 (en) 2011-10-17 2013-04-24 Pharmahungary 2000 Kft. Compounds for treatment of ischemic injury
EP2774989B1 (en) * 2011-11-02 2018-09-05 Osaka City University Double-stranded nucleic acid molecule for gene expression control
US20140323551A1 (en) * 2011-11-30 2014-10-30 Cedars-Sinai Medical Center Targeting micrornas mir-409-5p, mir-379 and mir-154* to treat prostate cancer bone metastasis and drug resistant lung cancer
CA2857712A1 (en) * 2011-12-01 2013-06-06 Cincinnati Children's Hospital Medical Center Materials and methods related to nsaid chemoprevention in colorectal cancer
AU2012347498A1 (en) * 2011-12-10 2014-06-26 Ohio State Innovation Foundation MiRNAs useful to reduce lung cancer tumorigenesis and chemotherapy resistance and related compositons and methods
CA2859430A1 (en) 2011-12-13 2013-06-20 Ohio State Innovation Foundation Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis
ITRM20110685A1 (it) 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
JP2015511121A (ja) 2012-01-20 2015-04-16 ジ・オハイオ・ステート・ユニバーシティ 浸潤性および予後に関する乳がんバイオマーカーシグネチャー
EP2844744A2 (en) 2012-02-22 2015-03-11 Brainstem Biotec Ltd. MicroRNAS FOR THE GENERATION OF ASTROCYTES
EP2844745A2 (en) 2012-02-22 2015-03-11 Brainstem Biotec Ltd. Generation of neural stem cells and motor neurons
WO2013133863A1 (en) 2012-03-09 2013-09-12 Thomson Licensing Distributed control of synchronized content
BR112014026639A8 (pt) 2012-04-25 2018-01-16 Regulus Therapeutics Inc compostos , métodos de inibição da atividade de mir-21 , método para diminuir a expressão de colágeno , método para tratar , prevenir ou atrasar o início de uma doença , método de tratamento de um distúrbio fibroproliferativo e usos de um composto.
US9598694B2 (en) 2012-05-02 2017-03-21 The Board Of Regents Of The University Of Texas System Micro-RNAs involved in macular degeneration
WO2013170146A1 (en) 2012-05-10 2013-11-14 Uab Research Foundation Methods and compositions for modulating mir-204 activity
JP6126088B2 (ja) 2012-05-26 2017-05-10 株式会社ボナック デリバリー機能を有する遺伝子発現制御用の一本鎖核酸分子
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
CN107236735B (zh) 2012-06-21 2019-11-08 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
CN104603272B (zh) * 2012-07-06 2017-11-07 宝生物工程株式会社 能够产生腺伴随病毒载体的细胞
EP3195869B1 (en) 2012-07-27 2021-09-29 Agency for Science, Technology and Research (A*STAR) Method of promoting wound healing
WO2014020608A1 (en) 2012-07-31 2014-02-06 Yeda Research And Development Co. Ltd. Methods of diagnosing and treating motor neuron diseases
ES2534210T3 (es) * 2012-08-29 2015-04-20 Chanel Parfums Beauté Inhibidores de micro-ARN para uso para prevenir y/o atenuar el envejecimiento cutáneo
EP2702998A1 (en) 2012-08-31 2014-03-05 IMBA-Institut für Molekulare Biotechnologie GmbH Therapeutic and diagnostic miRNA regulator in kidney disease
US20150344961A1 (en) * 2012-09-11 2015-12-03 New York University Sera Based miRNAs as Non-Invasive Biomarkers in Melanoma
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
EP3511423B2 (en) 2012-10-17 2024-05-29 Spatial Transcriptomics AB Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
WO2014071205A1 (en) * 2012-11-02 2014-05-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for diagnosis, prognosis and treatment of hematological malignancies
US9340787B2 (en) * 2012-11-15 2016-05-17 Yale University Compositions and methods of using micro RNAs
WO2014099999A1 (en) * 2012-12-18 2014-06-26 Sanford-Burnham Medical Research Institute Methods for improving cardiac contractility
DK2963125T3 (da) * 2013-02-15 2020-10-12 Univ Nat Corp Tokyo Medical & Dental Terapeutisk middel til behandling af en cancer, hvor NRF2 er stabiliseret
WO2014164753A1 (en) * 2013-03-11 2014-10-09 Emory University Methods and compositions for managing vascular conditions
US9006200B2 (en) * 2013-03-13 2015-04-14 Asbestos Diseases Research Foundation MicroRNA-based approach to treating malignant pleural mesothelioma
KR20150131312A (ko) 2013-03-15 2015-11-24 미르나 테라퓨틱스 인코포레이티드 마이크로rna 및 egfr-tki 억제제를 이용한 조합 암 치료
US9752143B2 (en) 2013-03-15 2017-09-05 MiRagen Therapeutics, Inc. Locked nucleic acid inhibitor of miR-145 and uses thereof
WO2014140856A2 (en) 2013-03-15 2014-09-18 Graham Lord Mir-142 and antagonists thereof for treating disease
US20160032383A1 (en) * 2013-03-15 2016-02-04 Albert Einstein College Of Medicine Of Yeshiva University PANEL OF microRNA BIOMARKERS IN HEALTHY AGING
WO2014168616A1 (en) 2013-04-10 2014-10-16 Thomson Licensing Tiering and manipulation of peer's heads in a telepresence system
JP2016169158A (ja) * 2013-06-14 2016-09-23 北海道公立大学法人 札幌医科大学 大腸癌を治療および／または診断するための組成物ならびにその利用
GB201310755D0 (en) * 2013-06-17 2013-07-31 Ucl Business Plc Therapy
US10284887B2 (en) 2013-06-20 2019-05-07 Interdigital Ce Patent Holdings System and method to assist synchronization of distributed play out of content
CA2914685A1 (en) 2013-06-24 2014-12-31 Mirna Therapeutics, Inc. Biomarkers of mir-34 activity
CA2916662C (en) 2013-06-25 2022-03-08 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US9862943B1 (en) * 2013-06-27 2018-01-09 California Institute Of Technology Long noncoding RNAs and cell reprogramming and differentiation
WO2015020122A1 (ja) * 2013-08-08 2015-02-12 国立大学法人 大阪大学 尿路上皮癌の診断または治療剤
KR101566586B1 (ko) * 2013-08-21 2015-11-16 서울대학교산학협력단 miRNA를 표적으로 하는 뇌전증 또는 발작 관련 질환의 예방 또는 치료용 약학 조성물 및 방법
WO2015044890A2 (en) * 2013-09-26 2015-04-02 Friedrich Miescher Institute For Biomedical Research Tools and methods using mirna 182, 96 and/or 183 for treating pathologies
US20150089870A1 (en) * 2013-10-01 2015-04-02 Wayne State University Population control of invasive plant species and restoration of native plant communities
KR101598070B1 (ko) * 2013-10-17 2016-02-26 한국과학기술연구원 마약 중독 예방 및 치료용 약제학적 조성물
PL3074050T3 (pl) 2013-10-28 2021-04-06 Icahn School Of Medicine At Mount Sinai Kompozycje i sposoby modulowania pobudliwości neuronalnej i zachowania motorycznego
KR101559131B1 (ko) * 2013-11-18 2015-10-07 한국원자력의학원 ｍｉＲＮＡ를 포함하는 방사선 민감성 증진용 조성물
CA2931082C (en) 2013-11-18 2024-01-23 Diamir, Llc Methods of using mirnas from bodily fluids for detection and monitoring of parkinson's disease (pd)
US20160319368A1 (en) 2013-12-17 2016-11-03 Csir A Method for Identification of Anti-HIV Human miRNA Mimics and miRNA Inhibitors and Anti-HIV Pharmaceutical Compounds
EP3088524A4 (en) 2013-12-26 2017-08-09 Tokyo Medical University Artificial mimic mirna for controlling gene expression, and use of same
KR102357337B1 (ko) * 2013-12-27 2022-01-28 가부시키가이샤 보낙 유전자 발현 제어를 위한 인공 매치형 miRNA 및 그 용도
WO2015099188A1 (ja) * 2013-12-27 2015-07-02 株式会社ボナック 遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途
JP2017506228A (ja) 2014-02-05 2017-03-02 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． セロトニン放出ホルモン、アドレナリン放出ホルモン、ノルアドレナリン放出ホルモン、グルタミン酸放出ホルモンおよび副腎皮質刺激ホルモン放出ホルモン関連の医学的状態の処置および診断のためのマイクロｒｎａおよび該マイクロｒｎａを含む組成物
WO2015133637A1 (ja) * 2014-03-07 2015-09-11 国立大学法人京都大学 マイクロｒｎａ封入ナノ粒子及びその医薬用途
US20160136181A1 (en) 2014-04-01 2016-05-19 Mirna Therapeutics, Inc Microrna dosing regimens
EP2940151A1 (en) * 2014-05-02 2015-11-04 Ruprecht-Karls-Universität Heidelberg Circulating miRNAs as early detection marker and prognostic marker
CA2953369A1 (en) * 2014-06-26 2015-12-30 Icahn School Of Medicine At Mount Sinai Method for diagnosing subclinical and clinical acute rejection by analysis of predictive gene sets
EP3170706A4 (en) * 2014-07-15 2018-03-28 Mitsuba Corporation Brushless wiper motor
LU92499B1 (en) 2014-07-16 2016-01-18 Univ Muenster Wilhelms Mirna 320a as biomarker for inflammatory bowel disease
ES2558262B2 (es) 2014-08-01 2016-07-14 Universidad Católica De Valencia "San Vicente Mártir" Método de diagnóstico de fibromialgia basado en microRNAs
MX2017001493A (es) 2014-08-07 2017-05-09 Regulus Therapeutics Inc Eleccion de micro acidos ribonucleicos (arn) como diana para trastornos metabolicos.
US20170298352A1 (en) 2014-09-30 2017-10-19 Research Institute at Nationwide Children's Hospit al Compositions and methods for treating hepatic fibrosis
BR112017013664A2 (pt) * 2014-12-27 2018-03-13 Bonac Corporation mirna de tipo natural, composição, métodos para inibir expressão de um gene alvo e para tratar uma doença, e, ácido nucleico de fita simples.
SG10201906716QA (en) 2015-01-20 2019-08-27 Miragen Therapeutics Inc Mir-92 inhibitors and uses thereof
GB201504772D0 (en) * 2015-03-20 2015-05-06 Univ Aston Preeclampsia
EP3273971A4 (en) 2015-03-27 2018-12-05 Yeda Research and Development Co. Ltd. Methods of treating motor neuron diseases
CN108064289A (zh) 2015-03-27 2018-05-22 株式会社博纳克 具有递送功能和基因表达调控能力的单链核酸分子
CA2982146A1 (en) 2015-04-10 2016-10-13 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
EP3284822A1 (en) * 2015-04-17 2018-02-21 The University of Tokyo Therapeutic agent for eye disease
US20180142297A1 (en) * 2015-05-14 2018-05-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for characterizing granulomatous diseases
WO2016190899A1 (en) * 2015-05-23 2016-12-01 Beem Alan M H Pri-mirna libraries and methods for making and using pri-mirna libraries
US10858627B2 (en) 2015-07-30 2020-12-08 Regents Of The University Of Minnesota Regulation of mesodermal specification
CN113694077A (zh) 2015-08-13 2021-11-26 索马根尼科斯公司 用于伤口愈合的短小发夹rna与微rna的组合物以及方法
WO2017032776A1 (en) * 2015-08-21 2017-03-02 Universitätsklinikum Jena Human micrornas for treatment of malignant tumours
US11285168B2 (en) 2015-09-28 2022-03-29 National University Corporation Chiba University Method for suppressing tumors by miR-200 family inhibition
US11180810B2 (en) 2015-09-29 2021-11-23 Research Institute At Nationwide Children's Hospital Methods for detecting hepatic fibrosis and responsiveness to therapy
JP6666002B2 (ja) * 2015-10-07 2020-03-13 国立大学法人京都大学 Ｔｄｐ−４３プロテノパシーの予防又は治療用組成物
WO2017098052A1 (en) * 2015-12-10 2017-06-15 Universität Für Bodenkultur Wien Compositions and methods for the diagnosis and treatment of bone fractures and disorders
EP3181698A1 (en) 2015-12-16 2017-06-21 European Molecular Biology Laboratory (EMBL) Microrna mir-142 as stem cell marker
US11041006B2 (en) 2015-12-28 2021-06-22 Riken Compositions for use in recovering or ameliorating deterioration of physiological functions due to aging
US10975436B2 (en) 2016-01-05 2021-04-13 Diamir, Llc Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders
CN105543225A (zh) * 2016-01-07 2016-05-04 华东师范大学 miR143及其诱导物LTA在制备抑制痤疮炎症药物中的应用
US10771508B2 (en) 2016-01-19 2020-09-08 Nadejda Sarmova Systems and methods for establishing a virtual shared experience for media playback
EP3423581A4 (en) 2016-03-04 2020-03-04 Rhode Island Hospital Targeting microrna for cancer treatment
EP3433381B1 (en) 2016-03-21 2024-07-24 Diamir, LLC Methods of using mirnas from bodily fluids for detection and differentiation of neurodegenerative diseases
WO2017179660A1 (ja) * 2016-04-14 2017-10-19 国立大学法人岐阜大学 マイクロｒｎａ－１４３誘導体
US11389479B2 (en) 2016-05-02 2022-07-19 University Of Massachusetts T cell differentiation and function regulation by decreasing let7 expression
CA3066107A1 (en) * 2016-06-03 2017-12-07 Hough Ear Institute Combination therapies for inner ear sensory hair cell regeneration/replacement
US10874688B2 (en) 2016-10-31 2020-12-29 Gifu University Double-stranded nucleic acid molecule and use thereof
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
CN107058470B (zh) * 2016-11-03 2020-09-01 中国人民解放军陆军军医大学 一种通过联合miR-136和miR-4791预测急性高山病发病风险的诊断试剂盒
CN110177544A (zh) 2016-11-29 2019-08-27 普尔泰克健康有限公司 用于递送治疗剂的外泌体
WO2018191895A1 (zh) 2017-04-19 2018-10-25 深圳市汇顶科技股份有限公司 光强检测方法、装置及智能终端
WO2018199231A1 (ja) * 2017-04-28 2018-11-01 一丸ファルコス株式会社 プラセンタ抽出物
WO2018204829A1 (en) * 2017-05-04 2018-11-08 University Of Maryland, Baltimore Methods for preventing neural tube defects in diabetic pregnancy
US20200199624A1 (en) * 2017-05-19 2020-06-25 Georgia State University Research Foundation, Inc. Recombinant oncolytic virus
KR102110103B1 (ko) * 2017-06-16 2020-05-13 (주)프로스테믹스 암의 예방 또는 치료용 약학적 조성물
US10781487B2 (en) 2017-07-24 2020-09-22 Diamir, Llc miRNA-based methods for detecting and monitoring aging
WO2019116234A1 (en) 2017-12-12 2019-06-20 Nestec S.A. Methods for determining microbiome ribosomal rna composition changes
JP2021518841A (ja) * 2018-03-14 2021-08-05 ベス イスラエル デアコネス メディカル センター マイクロｒｎａと肥満症
US12083143B2 (en) 2018-04-06 2024-09-10 University Of Massachusetts MLK-regulated microRNAs in angiogenesis and tumor development
US11519033B2 (en) 2018-08-28 2022-12-06 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
KR102115960B1 (ko) * 2018-11-28 2020-05-27 송미연 인간 중간엽 줄기세포를 갑상선 호르몬 분비세포로 분화 방법
US11649485B2 (en) 2019-01-06 2023-05-16 10X Genomics, Inc. Generating capture probes for spatial analysis
US11926867B2 (en) 2019-01-06 2024-03-12 10X Genomics, Inc. Generating capture probes for spatial analysis
CA3139919A1 (en) * 2019-03-11 2020-09-17 Ochsner Health System Microrna regulatory network as biomarkers of seizure in patients with spontaneous intracerebral hemorrhage
KR102248420B1 (ko) * 2019-03-15 2021-05-06 주식회사 제너로스 miR-142-3p의 표적 서열을 포함하는 재조합 벡터
US20220251552A1 (en) * 2019-03-25 2022-08-11 The Trustees Of The University Of Pennsylvania Regenerative Therapy Based on miRNA-302 Mimics for Enhancing Host Recovery from Pneumonia Caused by Streptococcus pneumoniae
JP2022529917A (ja) * 2019-04-18 2022-06-27 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ガンの処置及び予後のための方法
WO2020243579A1 (en) 2019-05-30 2020-12-03 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
US11198908B2 (en) 2019-06-17 2021-12-14 Biorchestra Co., Ltd. Method for diagnosis of Alzheimer's disease using microRNA
US10844380B1 (en) 2019-06-17 2020-11-24 Biorchestra Co., Ltd. Uses for prevention or treatment of brain diseases using microrna
CN110551809A (zh) * 2019-08-21 2019-12-10 昆明医科大学第一附属医院 miR-124在脊髓损伤修复中的用途
WO2021092433A2 (en) 2019-11-08 2021-05-14 10X Genomics, Inc. Enhancing specificity of analyte binding
EP4055185A1 (en) 2019-11-08 2022-09-14 10X Genomics, Inc. Spatially-tagged analyte capture agents for analyte multiplexing
WO2021133941A1 (en) * 2019-12-23 2021-07-01 University Of Massachusetts Oligonucleotides for tissue specific gene expression modulation
SG11202106899SA (en) 2019-12-23 2021-09-29 10X Genomics Inc Methods for spatial analysis using rna-templated ligation
US20210190770A1 (en) 2019-12-23 2021-06-24 10X Genomics, Inc. Compositions and methods for using fixed biological samples in partition-based assays
US11702693B2 (en) 2020-01-21 2023-07-18 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
US11821035B1 (en) 2020-01-29 2023-11-21 10X Genomics, Inc. Compositions and methods of making gene expression libraries
US12076701B2 (en) 2020-01-31 2024-09-03 10X Genomics, Inc. Capturing oligonucleotides in spatial transcriptomics
US11898205B2 (en) 2020-02-03 2024-02-13 10X Genomics, Inc. Increasing capture efficiency of spatial assays
US12110541B2 (en) 2020-02-03 2024-10-08 10X Genomics, Inc. Methods for preparing high-resolution spatial arrays
US11732300B2 (en) 2020-02-05 2023-08-22 10X Genomics, Inc. Increasing efficiency of spatial analysis in a biological sample
US12129516B2 (en) 2020-02-07 2024-10-29 10X Genomics, Inc. Quantitative and automated permeabilization performance evaluation for spatial transcriptomics
US11835462B2 (en) 2020-02-11 2023-12-05 10X Genomics, Inc. Methods and compositions for partitioning a biological sample
US11891654B2 (en) 2020-02-24 2024-02-06 10X Genomics, Inc. Methods of making gene expression libraries
US11926863B1 (en) 2020-02-27 2024-03-12 10X Genomics, Inc. Solid state single cell method for analyzing fixed biological cells
US11768175B1 (en) 2020-03-04 2023-09-26 10X Genomics, Inc. Electrophoretic methods for spatial analysis
EP4093870A4 (en) * 2020-03-13 2024-01-10 Duke University COMPOSITIONS FOR TREATING NASH AND RELATED DISEASES AND METHODS OF USING THE SAME
WO2021216708A1 (en) 2020-04-22 2021-10-28 10X Genomics, Inc. Methods for spatial analysis using targeted rna depletion
EP4153776A1 (en) 2020-05-22 2023-03-29 10X Genomics, Inc. Spatial analysis to detect sequence variants
WO2021236929A1 (en) 2020-05-22 2021-11-25 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
WO2021242834A1 (en) 2020-05-26 2021-12-02 10X Genomics, Inc. Method for resetting an array
AU2021283174A1 (en) 2020-06-02 2023-01-05 10X Genomics, Inc. Nucleic acid library methods
EP4158054A1 (en) 2020-06-02 2023-04-05 10X Genomics, Inc. Spatial transcriptomics for antigen-receptors
US12031177B1 (en) 2020-06-04 2024-07-09 10X Genomics, Inc. Methods of enhancing spatial resolution of transcripts
EP4421186A3 (en) 2020-06-08 2024-09-18 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
EP4165207B1 (en) 2020-06-10 2024-09-25 10X Genomics, Inc. Methods for determining a location of an analyte in a biological sample
WO2021263111A1 (en) 2020-06-25 2021-12-30 10X Genomics, Inc. Spatial analysis of dna methylation
US11761038B1 (en) 2020-07-06 2023-09-19 10X Genomics, Inc. Methods for identifying a location of an RNA in a biological sample
US12209280B1 (en) 2020-07-06 2025-01-28 10X Genomics, Inc. Methods of identifying abundance and location of an analyte in a biological sample using second strand synthesis
US11981960B1 (en) 2020-07-06 2024-05-14 10X Genomics, Inc. Spatial analysis utilizing degradable hydrogels
US11981958B1 (en) 2020-08-20 2024-05-14 10X Genomics, Inc. Methods for spatial analysis using DNA capture
CN112190592B (zh) * 2020-08-25 2022-03-11 苏州市立医院(北区) miRNA在制备防治骨关节炎药物的应用、miRNA高表达的外泌体和应用
US11926822B1 (en) 2020-09-23 2024-03-12 10X Genomics, Inc. Three-dimensional spatial analysis
WO2022076774A2 (en) * 2020-10-08 2022-04-14 The Trustees Of Columbia University In The City Of New York Treatment and detection of liver fibrosis and liver disease using microrna
CN112375823B (zh) * 2020-10-22 2022-09-16 上海交通大学医学院附属瑞金医院 miRNA抑制剂在制备治疗和/或预防淋巴瘤的药物中的应用
US11827935B1 (en) 2020-11-19 2023-11-28 10X Genomics, Inc. Methods for spatial analysis using rolling circle amplification and detection probes
EP4121555A1 (en) 2020-12-21 2023-01-25 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
EP4294571B8 (en) 2021-02-19 2024-07-10 10X Genomics, Inc. Method of using a modular assay support device
EP4301870B1 (en) 2021-03-18 2025-01-15 10X Genomics, Inc. Multiplex capture of gene and protein expression from a biological sample
WO2022221425A1 (en) 2021-04-14 2022-10-20 10X Genomics, Inc. Methods of measuring mislocalization of an analyte
EP4347879B1 (en) 2021-06-03 2025-02-19 10X Genomics, Inc. Methods, compositions, kits, and systems for enhancing analyte capture for spatial analysis
US20240301504A1 (en) * 2021-06-22 2024-09-12 The Curators Of The University Of Missouri Multianalyte biomarkers for lung cancer
WO2023034489A1 (en) 2021-09-01 2023-03-09 10X Genomics, Inc. Methods, compositions, and kits for blocking a capture probe on a spatial array
EP4305195A2 (en) 2021-12-01 2024-01-17 10X Genomics, Inc. Methods, compositions, and systems for improved in situ detection of analytes and spatial analysis
WO2023122033A1 (en) 2021-12-20 2023-06-29 10X Genomics, Inc. Self-test for pathology/histology slide imaging device
EP4453208A2 (en) 2021-12-23 2024-10-30 Boehringer Ingelheim International GmbH Methods and molecules for rna interference (rnai)
US11541116B1 (en) 2022-01-07 2023-01-03 Kojin Therapeutics, Inc. Methods and compositions for inducing ferroptosis in vivo
WO2024108031A2 (en) * 2022-11-16 2024-05-23 University Of Notre Dame Du Lac Mirna cocktail for treatment and prevention of fibrosis
KR102583230B1 (ko) * 2023-03-16 2023-09-27 재단법인 전남바이오산업진흥원 뇌경색 예방 또는 치료용 조성물

Family Cites Families (497)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2006A (en) * 1841-03-16 Clamp for crimping leather
US2007A (en) * 1841-03-16 Improvement in the mode of harvesting grain
US1529202A (en) 1924-07-16 1925-03-10 Joseph H Miller Festooning machine for carrying paper and the like
GB1529202A (en) 1976-02-20 1978-10-18 Ciba Geigy Ag Spectral sensitising dyes
US5583013A (en) 1977-11-08 1996-12-10 Genentech, Inc. Method and means for microbial polypeptide expression
US5221619A (en) 1977-11-08 1993-06-22 Genentech, Inc. Method and means for microbial polypeptide expression
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
JPS55116259A (en) 1979-03-01 1980-09-06 Fuji Photo Film Co Ltd Microimmunoassay method
DE3170135D1 (en) 1980-09-02 1985-05-30 Fuji Photo Film Co Ltd Method for immunochemical measurement of trace components
JPS5745460A (en) 1980-09-02 1982-03-15 Fuji Photo Film Co Ltd Inspection sheet for measuring trace component and inspecting method using said sheet
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4849513A (en) 1983-12-20 1989-07-18 California Institute Of Technology Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US4828979A (en) 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE3529478A1 (de) 1985-08-16 1987-02-19 Boehringer Mannheim Gmbh 7-desaza-2'desoxyguanosin-nukleotide, verfahren zu deren herstellung und deren verwendung zur nukleinsaeure-sequenzierung
US4682195A (en) 1985-09-30 1987-07-21 General Electric Company Insulated gate device with configured emitter contact pad
US4959463A (en) 1985-10-15 1990-09-25 Genentech, Inc. Intermediates
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
US5011769A (en) * 1985-12-05 1991-04-30 Meiogenics U.S. Limited Partnership Methods for detecting nucleic acid sequences
US4876187A (en) 1985-12-05 1989-10-24 Meiogenics, Inc. Nucleic acid compositions with scissile linkage useful for detecting nucleic acid sequences
US4910300A (en) 1985-12-11 1990-03-20 Chiron Corporation Method for making nucleic acid probes
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US5268486A (en) 1986-04-18 1993-12-07 Carnegie-Mellon Unversity Method for labeling and detecting materials employing arylsulfonate cyanine dyes
EP0266032A1 (en) 1986-08-29 1988-05-04 Beecham Group Plc Modified fibrinolytic enzyme
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US4816571A (en) 1987-06-04 1989-03-28 Applied Biosystems, Inc. Chemical capping by phosphitylation during oligonucleotide synthesis
GB8803000D0 (en) 1988-02-10 1988-03-09 Ekins Roger Philip Determination of ambient concentrations of several analytes
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US4999290A (en) * 1988-03-31 1991-03-12 The Board Of Regents, The University Of Texas System Detection of genomic abnormalities with unique aberrant gene transcripts
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5602244A (en) 1988-05-26 1997-02-11 Competitive Technologies, Inc. Polynucleotide phosphorodithioate compounds
GB8822228D0 (en) 1988-09-21 1988-10-26 Southern E M Support-bound oligonucleotides
US5708154A (en) 1989-02-24 1998-01-13 City Of Hope RNA-DNA hybrid molecules of nucleic acid
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6867195B1 (en) 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5871928A (en) 1989-06-07 1999-02-16 Fodor; Stephen P. A. Methods for nucleic acid analysis
US5242974A (en) 1991-11-22 1993-09-07 Affymax Technologies N.V. Polymer reversal on solid surfaces
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
DE3924454A1 (de) 1989-07-24 1991-02-07 Cornelis P Prof Dr Hollenberg Die anwendung von dna und dna-technologie fuer die konstruktion von netzwerken zur verwendung in der chip-konstruktion und chip-produktion (dna chips)
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5141813A (en) 1989-08-28 1992-08-25 Clontech Laboratories, Inc. Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis
GB8920097D0 (en) 1989-09-06 1989-10-18 Ici Plc Amplification processes
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US5366860A (en) 1989-09-29 1994-11-22 Applied Biosystems, Inc. Spectrally resolvable rhodamine dyes for nucleic acid sequence determination
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
CA2071510C (en) 1989-10-24 2004-07-06 Chris A. Buhr 2' modified oligonucleotides
US5188934A (en) * 1989-11-14 1993-02-23 Applied Biosystems, Inc. 4,7-dichlorofluorescein dyes as molecular probes
EP0430881A3 (en) 1989-11-29 1991-10-23 Ciba-Geigy Ag Photochromic compounds, process for their preparation and their use
US5486603A (en) * 1990-01-08 1996-01-23 Gilead Sciences, Inc. Oligonucleotide having enhanced binding affinity
US5859221A (en) 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US5872232A (en) 1990-01-11 1999-02-16 Isis Pharmaceuticals Inc. 2'-O-modified oligonucleotides
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
US5223618A (en) 1990-08-13 1993-06-29 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analog compounds
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
ATE154246T1 (de) 1990-07-27 1997-06-15 Isis Pharmaceuticals Inc Nuklease resistente, pyrimidin modifizierte oligonukleotide, die die gen-expression detektieren und modulieren
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5965364A (en) 1990-10-09 1999-10-12 Benner; Steven Albert Method for selecting functional deoxyribonucleotide derivatives
WO1992007095A1 (en) * 1990-10-15 1992-04-30 Stratagene Arbitrarily primed polymerase chain reaction method for fingerprinting genomes
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US6287792B1 (en) 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
AU662906B2 (en) 1991-06-26 1995-09-21 F. Hoffmann-La Roche Ag Methods for detection of carcinoma metastases by nucleic acid amplification
US6369209B1 (en) 1999-05-03 2002-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5639603A (en) 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
IL103674A0 (en) 1991-11-19 1993-04-04 Houston Advanced Res Center Method and apparatus for molecule detection
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5256555A (en) 1991-12-20 1993-10-26 Ambion, Inc. Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US5260191A (en) 1992-01-30 1993-11-09 Agracetus, Inc. Method for diagnosing tumors
US5652099A (en) 1992-02-12 1997-07-29 Conrad; Michael J. Probes comprising fluorescent nucleosides and uses thereof
ATE244259T1 (de) 1992-02-12 2003-07-15 Chromagen Inc Verwendungen von fluoreszierenden n-nukleosiden und dessen analogen
DE4204650C1 (es) 1992-02-15 1993-07-08 Hoffmeister, Helmut, Dr., 4400 Muenster, De
CA2130562A1 (en) 1992-02-19 1993-09-02 Alexander B. Chetverin Novel oligonucleotide arrays and their use for sorting, isolating, sequencing, and manipulating nucleic acids
US5262311A (en) 1992-03-11 1993-11-16 Dana-Farber Cancer Institute, Inc. Methods to clone polyA mRNA
CA2102784A1 (en) 1992-03-11 1993-09-12 Peng Liang Identifying, isolating and cloning messenger rnas
WO1993020236A1 (en) 1992-04-03 1993-10-14 Applied Biosystems, Inc. Probe composition and method
GB9208545D0 (en) 1992-04-21 1992-06-03 Gatsby Charitable Foundation T Virus resistant plants
US5428148A (en) 1992-04-24 1995-06-27 Beckman Instruments, Inc. N4 - acylated cytidinyl compounds useful in oligonucleotide synthesis
DE69334225D1 (de) 1992-07-07 2008-07-31 Japan Tobacco Inc Verfahren zur transformation einer monokotyledon pflanze
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
CA2140910C (en) 1992-07-27 1999-03-23 Jeffrey A. Townsend An improved method of agrobacterium-mediated transformation of cultured soybean cells
US5438131A (en) 1992-09-16 1995-08-01 Bergstrom; Donald E. 3-nitropyrrole nucleoside
US5554501A (en) 1992-10-29 1996-09-10 Beckman Instruments, Inc. Biopolymer synthesis using surface activated biaxially oriented polypropylene
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
US5858988A (en) 1993-02-24 1999-01-12 Wang; Jui H. Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5580726A (en) 1994-04-29 1996-12-03 Geron Corporation Method and Kit for enhanced differential display
US5767259A (en) * 1994-12-27 1998-06-16 Naxcor Oligonucleotides containing base-free linking groups with photoactivatable side chains
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5470710A (en) 1993-10-22 1995-11-28 University Of Utah Automated hybridization/imaging device for fluorescent multiplex DNA sequencing
US5472672A (en) 1993-10-22 1995-12-05 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and method for polymer synthesis using arrays
EP0730663B1 (en) 1993-10-26 2003-09-24 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6045996A (en) 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
US5429807A (en) 1993-10-28 1995-07-04 Beckman Instruments, Inc. Method and apparatus for creating biopolymer arrays on a solid support surface
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5538848A (en) * 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
WO1995014106A2 (en) 1993-11-17 1995-05-26 Id Biomedical Corporation Cycling probe cleavage detection of nucleic acid sequences
US5610287A (en) 1993-12-06 1997-03-11 Molecular Tool, Inc. Method for immobilizing nucleic acid molecules
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
GB9401833D0 (en) 1994-02-01 1994-03-30 Isis Innovation Method for discovering ligands
WO1995021944A1 (en) 1994-02-14 1995-08-17 Smithkline Beecham Corporation Differentially expressed genes in healthy and diseased subjects
DE4406524A1 (de) 1994-02-28 1995-08-31 Boehringer Mannheim Gmbh 3'-RNA-Markierung mit Terminaler Transferase
US5877302A (en) 1994-03-23 1999-03-02 Case Western Reserve University Compacted nucleic acids and their delivery to cells
US5972901A (en) 1994-03-23 1999-10-26 Case Western Reserve University Serpin enzyme complex receptor--mediated gene transfer
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5844107A (en) 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US6146886A (en) 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5574146A (en) 1994-08-30 1996-11-12 Beckman Instruments, Inc. Oligonucleotide synthesis with substituted aryl carboxylic acids as activators
US5554744A (en) 1994-09-23 1996-09-10 Hybridon, Inc. Method for loading solid supports for nucleic acid synthesis
US6096314A (en) 1994-10-07 2000-08-01 Yeda Research And Development Co. Ltd. Peptides and pharmaceutical compositions comprising them
US5604097A (en) 1994-10-13 1997-02-18 Spectragen, Inc. Methods for sorting polynucleotides using oligonucleotide tags
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
WO1997027317A1 (en) 1996-01-23 1997-07-31 Affymetrix, Inc. Nucleic acid analysis techniques
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
AU5310296A (en) * 1995-03-17 1996-10-08 John Wayne Cancer Institute Detection of melanoma or breast metastases with a multiple marker assay
US5801155A (en) * 1995-04-03 1998-09-01 Epoch Pharmaceuticals, Inc. Covalently linked oligonucleotide minor grove binder conjugates
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
US5624711A (en) 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
DE19518505A1 (de) 1995-05-19 1996-11-21 Max Planck Gesellschaft Verfahren zur Genexpressionsanalyse
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
EP0832271B8 (en) 1995-06-07 2005-03-02 INEX Pharmaceuticals Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6111095A (en) 1995-06-07 2000-08-29 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US6998268B2 (en) 1995-07-03 2006-02-14 Dainippon Sumitomo Pharma Co. Ltd. Gene preparations
US5637683A (en) 1995-07-13 1997-06-10 Cornell Research Foundation, Inc. Nucleic acid analog with amide linkage and method of making that analog
US5661028A (en) 1995-09-29 1997-08-26 Lockheed Martin Energy Systems, Inc. Large scale DNA microsequencing device
US5658734A (en) 1995-10-17 1997-08-19 International Business Machines Corporation Process for synthesizing chemical compounds
US5705629A (en) 1995-10-20 1998-01-06 Hybridon, Inc. Methods for H-phosphonate synthesis of mono- and oligonucleotides
US6418382B2 (en) * 1995-10-24 2002-07-09 Curagen Corporation Method and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing
US5871697A (en) * 1995-10-24 1999-02-16 Curagen Corporation Method and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing
US20040142895A1 (en) 1995-10-26 2004-07-22 Sirna Therapeutics, Inc. Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5998203A (en) * 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
EP0880598A4 (en) * 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
US5837196A (en) 1996-01-26 1998-11-17 The Regents Of The University Of California High density array fabrication and readout method for a fiber optic biosensor
US5670663A (en) 1996-02-14 1997-09-23 Regents Of The University Of California Recovery of taxanes from conifers
US6020481A (en) * 1996-04-01 2000-02-01 The Perkin-Elmer Corporation Asymmetric benzoxanthene dyes
US6458530B1 (en) 1996-04-04 2002-10-01 Affymetrix Inc. Selecting tag nucleic acids
DE69738687D1 (de) 1996-04-12 2008-06-26 Phri Properties Inc Sonden, kits und assays
US5800996A (en) 1996-05-03 1998-09-01 The Perkin Elmer Corporation Energy transfer dyes with enchanced fluorescence
US5847162A (en) 1996-06-27 1998-12-08 The Perkin Elmer Corporation 4, 7-Dichlororhodamine dyes
US5863727A (en) * 1996-05-03 1999-01-26 The Perkin-Elmer Corporation Energy transfer dyes with enhanced fluorescence
US5945526A (en) 1996-05-03 1999-08-31 Perkin-Elmer Corporation Energy transfer dyes with enhanced fluorescence
US6184037B1 (en) 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
US5739169A (en) * 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
SE506700C2 (sv) 1996-05-31 1998-02-02 Mikael Kubista Sond och förfaranden för analys av nukleinsyra
DE69735313T2 (de) * 1996-06-04 2006-11-02 University Of Utah Research Foundation, Salt Lake City Fluoreszenz-Donor-Akzeptor Paar
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US6770291B2 (en) 1996-08-30 2004-08-03 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
GB9618050D0 (en) 1996-08-29 1996-10-09 Cancer Res Campaign Tech Global amplification of nucleic acids
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US5886165A (en) 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
AU6545898A (en) 1997-03-07 1998-09-22 Reprogen, Inc. Method for identifying hormonally modulated genes
CN1226930A (zh) 1997-03-10 1999-08-25 日本烟草产业株式会社 反义核苷酸序列
US6251666B1 (en) 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
US6090556A (en) 1997-04-07 2000-07-18 Japan Science & Technology Corporation Method for quantitatively determining the expression of a gene
NO972006D0 (no) 1997-04-30 1997-04-30 Forskningsparken I Aas As Ny metode for diagnose av sykdommer
US6287591B1 (en) 1997-05-14 2001-09-11 Inex Pharmaceuticals Corp. Charged therapeutic agents encapsulated in lipid particles containing four lipid components
US6262252B1 (en) 1997-05-19 2001-07-17 Mirus, Inc. Single-step method for labeling nucleic acids with mustard or aziridine labeling reagents
US5919626A (en) 1997-06-06 1999-07-06 Orchid Bio Computer, Inc. Attachment of unmodified nucleic acids to silanized solid phase surfaces
ATE319856T1 (de) 1997-06-13 2006-03-15 Affymetrix Inc A Delaware Corp Verfahren zur erkennung von genpolymorphismen und allelexpression unter verwendung von sondenchips
US6008379A (en) 1997-10-01 1999-12-28 The Perkin-Elmer Corporation Aromatic-substituted xanthene dyes
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US6485901B1 (en) 1997-10-27 2002-11-26 Boston Probes, Inc. Methods, kits and compositions pertaining to linear beacons
DE69841849D1 (de) * 1997-10-27 2010-09-30 Boston Probes Inc Sich auf "pna molecular beacons" beziehende verfahren, testsätze und zusammensetzungen
ATE537270T1 (de) 1997-10-30 2011-12-15 Cold Spring Harbor Lab Sondenanordnungen und deren verwendungen für verfahren zur dns-unterscheidung
US5936087A (en) * 1997-11-25 1999-08-10 The Perkin-Elmer Corporation Dibenzorhodamine dyes
US6238869B1 (en) * 1997-12-19 2001-05-29 High Throughput Genomics, Inc. High throughput assay system
US6232066B1 (en) * 1997-12-19 2001-05-15 Neogen, Inc. High throughput assay system
US6458533B1 (en) 1997-12-19 2002-10-01 High Throughput Genomics, Inc. High throughput assay system for monitoring ESTs
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6121058A (en) 1998-01-02 2000-09-19 Intel Corporation Method for removing accumulated solder from probe card probing features
US6087102A (en) 1998-01-07 2000-07-11 Clontech Laboratories, Inc. Polymeric arrays and methods for their use in binding assays
US6269846B1 (en) 1998-01-13 2001-08-07 Genetic Microsystems, Inc. Depositing fluid specimens on substrates, resulting ordered arrays, techniques for deposition of arrays
US5942398A (en) 1998-02-26 1999-08-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glutx and uses thereof
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
CA2326823A1 (en) 1998-04-20 1999-10-28 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
US6037129A (en) * 1998-05-28 2000-03-14 Medical University Of South Carolina Multi-marker RT-PCR panel for detecting metastatic breast cancer
FR2780059B1 (fr) 1998-06-17 2002-10-11 Bio Merieux Procede de marquage d'un acide ribonucleique et fragments d'arn marques ainsi obtenus
US6576420B1 (en) 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
GB9815799D0 (en) 1998-07-21 1998-09-16 Pharmagene Lab Limited Quantitative analysis of gene expression
US6730477B1 (en) * 1998-08-04 2004-05-04 Diadexus, Inc. Method of diagnosing, monitoring and staging breast cancer
US6140054A (en) 1998-09-30 2000-10-31 University Of Utah Research Foundation Multiplex genotyping using fluorescent hybridization probes
WO2000024939A1 (en) 1998-10-27 2000-05-04 Affymetrix, Inc. Complexity management and analysis of genomic dna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
GB9904991D0 (en) * 1999-03-05 1999-04-28 Univ Nottingham Genetic screening
ATE465168T1 (de) 1999-03-18 2010-05-15 Exiqon As Xylo-lna analoge
US6383752B1 (en) * 1999-03-31 2002-05-07 Hybridon, Inc. Pseudo-cyclic oligonucleobases
US6103576A (en) * 1999-04-13 2000-08-15 Microchip Technology Incorporated Dielectric layer of a memory cell having a stacked oxide sidewall and method of fabricating same
NZ514348A (en) 1999-05-04 2004-05-28 Exiqon As L-ribo-LNA analogues
US6638717B2 (en) 1999-05-19 2003-10-28 Aventis Pharmaceuticals, Inc. Microarray-based subtractive hybridzation
WO2000071096A2 (en) 1999-05-24 2000-11-30 Introgen Therapeutics, Inc. Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US6132997A (en) 1999-05-28 2000-10-17 Agilent Technologies Method for linear mRNA amplification
KR100903243B1 (ko) 1999-06-03 2009-06-17 제시 엘. 에스. 에이유 세포증식 및 세포사를 조절하기 위한 방법 및 조성물
WO2000075356A1 (en) 1999-06-04 2000-12-14 Lin Shi Lung Rna polymerase chain reaction
US6964847B1 (en) 1999-07-14 2005-11-15 Packard Biosciences Company Derivative nucleic acids and uses thereof
US6201112B1 (en) 1999-07-22 2001-03-13 Agilent Technologies Inc. Method for 3′ end-labeling ribonucleic acids
US7005261B1 (en) * 1999-07-29 2006-02-28 British Biocell International Limited Method for detecting nucleic acid target sequences involving in vitro transcription from an RNA polymerase promoter
US6140500A (en) 1999-09-03 2000-10-31 Pe Corporation Red-emitting [8,9]benzophenoxazine nucleic acid dyes and methods for their use
US6511832B1 (en) * 1999-10-06 2003-01-28 Texas A&M University System In vitro synthesis of capped and polyadenylated mRNAs using baculovirus RNA polymerase
US20020094546A1 (en) 1999-10-07 2002-07-18 Shimkets Richard A. Growth factor polypeptides and nucleic acids encoding same
JP2003516124A (ja) 1999-10-15 2003-05-13 ユニバーシティー オブ マサチューセッツ 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子
US6528254B1 (en) * 1999-10-29 2003-03-04 Stratagene Methods for detection of a target nucleic acid sequence
US6191278B1 (en) * 1999-11-03 2001-02-20 Pe Corporation Water-soluble rhodamine dyes and conjugates thereof
US6458382B1 (en) 1999-11-12 2002-10-01 Mirus Corporation Nucleic acid transfer complexes
US6435245B1 (en) 1999-11-18 2002-08-20 Pitney Bowes Inc. System for folding and tabbing sheets
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
JP2003515149A (ja) 1999-11-26 2003-04-22 キュラジェン コーポレイション 核酸プローブアレイ
US6383749B2 (en) 1999-12-02 2002-05-07 Clontech Laboratories, Inc. Methods of labeling nucleic acids for use in array based hybridization assays
US7205105B2 (en) * 1999-12-08 2007-04-17 Epoch Biosciences, Inc. Real-time linear detection probes: sensitive 5′-minor groove binder-containing probes for PCR analysis
AU2001234608A1 (en) 2000-01-28 2001-08-07 Genetrace Systems, Inc. Methods for analysis of gene expression
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
WO2002081628A2 (en) 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
US20020065406A1 (en) 2000-03-24 2002-05-30 Meyers Rachel A. 18221, a novel dual specificity phosphatase and uses thereof
US6447723B1 (en) 2000-03-13 2002-09-10 Packard Instrument Company, Inc. Microarray spotting instruments incorporating sensors and methods of using sensors for improving performance of microarray spotting instruments
US20030084471A1 (en) * 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
US20020037540A1 (en) 2000-03-23 2002-03-28 Shujath Ali Compositions and methods of diagnosing, monitoring, staging, imaging and treating prostate cancer
JP2004501613A (ja) 2000-03-27 2004-01-22 ディアデクサス　インコーポレーテッド 乳腺癌の診断、モニタリング、ステージング、イメージング及び処置のための組成物並びに方法
AU2001251013A1 (en) 2000-03-28 2001-10-08 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
WO2001072775A2 (en) 2000-03-29 2001-10-04 Diadexus, Inc. Polynucleotides and polypeptides as well as methods for diagnosing and treating lung cancer
AU2001251223A1 (en) 2000-03-30 2001-10-15 Diadexus, Inc. Compositions and methods for diagnosing, monitoring, staging, imaging and treating stomach cancer
IL151928A0 (en) * 2000-03-30 2003-04-10 Whitehead Biomedical Inst Rna sequence-specific mediators of rna interference
US6573048B1 (en) * 2000-04-18 2003-06-03 Naxcor Degradable nucleic acid probes and nucleic acid detection methods
US7947275B2 (en) 2000-05-10 2011-05-24 Signe Biopharma, Inc. Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth
US20020042388A1 (en) 2001-05-01 2002-04-11 Cooper Mark J. Lyophilizable and enhanced compacted nucleic acids
EP2279757A3 (en) 2000-06-02 2011-08-03 Bracco Suisse SA Compounds for targeting endothelial cells
AU2001270164A1 (en) 2000-06-26 2002-01-08 The United States Of America As Represented By The Secretary Of Agriculture Production of vaccines using transgenic plants
AU2001276371A1 (en) 2000-06-30 2002-01-14 Epigenomics Ag Method and nucleic acids for analysing the methylation of genes implicated pharmacogenomics
US6596490B2 (en) * 2000-07-14 2003-07-22 Applied Gene Technologies, Inc. Nucleic acid hairpin probes and uses thereof
JP4180365B2 (ja) 2000-07-31 2008-11-12 エフ．ホフマン−ラ ロシュ アーゲー ピペラジン誘導体
US6797471B2 (en) 2000-08-04 2004-09-28 Board Of Regents, The University Of Texas System Detection and diagnosis of smoking related cancers
JP2002067789A (ja) * 2000-09-05 2002-03-08 Yazaki Corp ランプユニットの電線接続構造
WO2002024718A1 (en) 2000-09-19 2002-03-28 Diadexus, Inc. Compositions and methods relating to prostate specific genes and proteins
US20030082604A1 (en) 2000-09-27 2003-05-01 Swanson Melvin J. High density arrays
US7162371B1 (en) 2000-10-11 2007-01-09 Georgia Tech Research Corporation Differentially-expressed conifer cDNAs, and their use in improving somatic embryogenesis
US6617112B2 (en) 2000-10-11 2003-09-09 Monsanto Technology Llc Methods for gene array analysis of nuclear runoff transcripts
US6350580B1 (en) * 2000-10-11 2002-02-26 Stratagene Methods for detection of a target nucleic acid using a probe comprising secondary structure
US20020150626A1 (en) 2000-10-16 2002-10-17 Kohane Daniel S. Lipid-protein-sugar particles for delivery of nucleic acids
WO2002048168A1 (en) * 2000-10-24 2002-06-20 Isis Pharmaceuticals, Inc. Antisense modulation of tnfr1 expression
US7001724B1 (en) * 2000-11-28 2006-02-21 Applera Corporation Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
SI1407044T2 (en) 2000-12-01 2018-03-30 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Rna interference mediating small rna molecules
CA2364294C (en) 2000-12-04 2013-04-02 Primagen B.V. Testing endosymbiont cellular organelles and compounds identifiable therewith
US20030099976A1 (en) 2001-01-17 2003-05-29 Tai-Jay Chang Androgen receptor complex-associated protein
WO2002057496A2 (en) 2001-01-18 2002-07-25 Socratech L.L.C. Gene expression profiling of endothelium in alzheimer's disease
US7015047B2 (en) * 2001-01-26 2006-03-21 Aviva Biosciences Corporation Microdevices having a preferential axis of magnetization and uses thereof
US20040110191A1 (en) * 2001-01-31 2004-06-10 Winkler Matthew M. Comparative analysis of nucleic acids using population tagging
WO2002064835A2 (en) 2001-01-31 2002-08-22 Ambion, Inc. Methods for nucleic acid fingerprint analysis
US20040058373A1 (en) * 2001-01-31 2004-03-25 Winkler Matthew M. Competitive amplification of fractionated targets from multiple nucleic acid samples
WO2002073504A1 (en) 2001-03-14 2002-09-19 Gene Logic, Inc. A system and method for retrieving and using gene expression data from multiple sources
US20030170623A1 (en) 2001-04-13 2003-09-11 Jingwen Chen Multiplexed gene analysis on a mobile solid support
EP1390387A4 (en) 2001-04-20 2004-12-08 Ludwig Inst Cancer Res TESTICLES CANCER ANTIGENS
EP1399460A4 (en) 2001-04-27 2005-04-13 Sunnybrook & Women S College H GENESIS ASSOCIATED WITH BREAST CANCER AND THEIR USE
JP2004535388A (ja) 2001-04-30 2004-11-25 ターゲティッド ジェネティクス コーポレイション 脂質含有薬物送達複合体およびそれらの生成方法
AUPR480901A0 (en) 2001-05-04 2001-05-31 Genomics Research Partners Pty Ltd Diagnostic method for assessing a condition of a performance animal
US20040209832A1 (en) 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2003070917A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. Rna interference mediated inhibition of myc and myb genes or genes of their respective pathways
AU2002303912A1 (en) 2001-06-01 2002-12-16 Prosanos Corporation Information processing method for disease stratification and assessment of disease progressing
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
US20040086504A1 (en) 2001-06-21 2004-05-06 Deepak Sampath Cyr61 as a target for treatment and diagnosis of breast cancer
AU2002315413A1 (en) 2001-06-22 2003-01-08 Gene Logic, Inc. Platform for management and mining of genomic data
WO2003001985A2 (en) 2001-06-28 2003-01-09 Dermtech International Method for detection of melanoma
KR20040014997A (ko) 2001-06-29 2004-02-18 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 Ｔ 세포 조절 유전자 및 그것의 사용방법
WO2003087297A2 (en) 2001-08-08 2003-10-23 North Carolina State University Infectious disease microarray
AU2002331777A1 (en) 2001-08-30 2003-03-18 Spectral Genomics, Inc. Arrays comprising pre-labeled biological molecules and methods for making and using these arrays
US20030198627A1 (en) * 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
AU2002339865A1 (en) 2001-09-05 2003-03-18 The Children's Hospital Of Philadelphia Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
US20040241696A1 (en) 2001-09-06 2004-12-02 Peinado Miguel A Genetic analysis of biological samples in arrayed expanded representations of their nucleic acids
JP2005528582A (ja) 2001-09-07 2005-09-22 コーニング インコーポレイテッド ハイスループット分析のためのマイクロカラム・プラットフォームに基づくアレイ
CA2460639C (en) * 2001-09-19 2013-07-16 Alexion Pharmaceuticals, Inc. Engineered templates and their use in single primer amplification
IL159422A0 (en) * 2001-09-20 2004-06-01 Cornell Res Foundation Inc Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
US6593091B2 (en) * 2001-09-24 2003-07-15 Beckman Coulter, Inc. Oligonucleotide probes for detecting nucleic acids through changes in flourescence resonance energy transfer
EP2385122B1 (en) * 2001-09-28 2018-04-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
WO2003029485A2 (en) 2001-10-02 2003-04-10 Azign Bioscience A/S Specific differential display arrays
AU2002367886B8 (en) 2001-10-12 2008-08-14 Perkinelmer Las, Inc. Compilations of nucleic acids and arrays and methods of using them
US20040063654A1 (en) * 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
WO2004033620A2 (en) 2001-11-02 2004-04-22 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
WO2003040410A1 (en) 2001-11-02 2003-05-15 Nimblegen Systems, Inc. Detection of hybridization oligonucleotide microarray through covalently labeling microarray probe
JP2005516183A (ja) 2001-11-19 2005-06-02 プロトメトリックス，インコーポレーテッド 検体を検出および測定するための非抗体タンパク質の使用方法
AU2002357368A1 (en) 2001-12-19 2003-07-09 Affymetrix, Inc. Array plates and method for constructing array plates
AU2002360773A1 (en) * 2001-12-27 2003-07-24 Agy Therapeutics, Inc. Use of biomolecular targets in the treatment and visualization of tumors
US7141372B2 (en) 2002-01-18 2006-11-28 Health Research Incorporated Universal RT-coupled PCR method for the specific amplification of mRNA
EP1470255A2 (en) 2002-01-30 2004-10-27 Epigenomics AG Identification of cell differentiation states based on methylation patterns
CA2474530A1 (en) 2002-02-07 2003-08-14 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Diagnostic microarray and method of use thereof
US20030232356A1 (en) 2002-02-08 2003-12-18 Dooley Thomas P. Skin cell biomarkers and methods for identifying biomarkers using nucleic acid microarrays
WO2003076928A1 (en) 2002-03-07 2003-09-18 University Of Utah Research Foundation Methods for identifying large subsets of differentially expressed genes based on multivariate microarray data analysis
US20040001841A1 (en) 2002-04-03 2004-01-01 Usha Nagavarapu Use of biomolecular targets in the treatment and visualization of brain tumors
US20070025997A1 (en) 2002-04-03 2007-02-01 Usha Nagavarapu Use of biomolecular targets in the treatment and visualization of brain tumors
DK1504126T3 (da) 2002-05-03 2014-06-10 Univ Duke Fremgangsmåde til regulering af genekspression
DE60323625D1 (de) 2002-05-03 2008-10-30 Vialogy Llc Verfahren zur charakterisierung der ausgangssignale eines microarrays
CA2482031A1 (en) 2002-05-20 2004-03-04 Northrop Grumman Corporation Point source biological agent detection system
WO2003100012A2 (en) 2002-05-24 2003-12-04 Nimblegen Systems, Inc. Microarrays and method for running hybridization reaction for multiple samples on a single microarray
AUPS261402A0 (en) 2002-05-28 2002-06-20 Compusign Pty Ltd Array monitoring
US20030228579A1 (en) 2002-06-05 2003-12-11 Uri Alon Ordering genes by analysis of expression kinetics
US7452987B2 (en) 2002-08-05 2008-11-18 Silence Therapeutics Aktiengesellschaft (Ag) Interfering RNA molecules
WO2004014933A1 (en) * 2002-08-07 2004-02-19 University Of Massachusetts Compositions for rna interference and methods of use thereof
US20040029121A1 (en) 2002-08-08 2004-02-12 Susan Cottrell Methods and nucleic acids for the analysis of CpG dinucleotide methylation status associated with the calcitonin gene
US20040029128A1 (en) 2002-08-08 2004-02-12 Epigenomics, Inc. Methods and nucleic acids for the analysis of CpG dinucleotide methylation status associated with the calcitonin gene
EP1560924A4 (en) 2002-08-16 2006-05-31 Wayne John Cancer Inst MOLECULAR LYMPHATIC MAPPING OF VIRCHOV LYMPHOTIC NODES
AU2003270654A1 (en) 2002-09-12 2004-04-30 Baylor College Of Medecine System and method for image segmentation
EP1556506A1 (en) 2002-09-19 2005-07-27 The Chancellor, Masters And Scholars Of The University Of Oxford Molecular arrays and single molecule detection
CA2500224C (en) 2002-09-25 2015-04-28 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
WO2004041212A2 (en) 2002-11-01 2004-05-21 Todd Charlton Sacktor Apkc isoforms in nervous system disorders and cancer
EP1418241A1 (en) 2002-11-08 2004-05-12 PrimaGen Holding B.V. Method for quantifying a ratio between at least two nucleic acid sequences
EP1567007B1 (en) 2002-11-13 2012-02-22 Thomas Jefferson University Compositions and methods for cancer diagnosis and therapy
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7655785B1 (en) 2002-11-14 2010-02-02 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
US20040214198A1 (en) 2002-11-15 2004-10-28 University Of Massachusetts Allele-targeted RNA interference
US20040175732A1 (en) * 2002-11-15 2004-09-09 Rana Tariq M. Identification of micrornas and their targets
JPWO2004050125A1 (ja) 2002-12-03 2006-03-30 株式会社高研 腫瘍細胞の増殖及び／又は浸潤の抑制剤
US7851150B2 (en) * 2002-12-18 2010-12-14 Third Wave Technologies, Inc. Detection of small nucleic acids
EP2361991A1 (en) * 2002-12-18 2011-08-31 Third Wave Technologies, Inc. Detection of small nucleic acids
KR20050100371A (ko) 2003-01-13 2005-10-18 에모리 유니버시티 정상 및 암세포에서의 유전자 발현의 검출 방법
CN1761756B (zh) 2003-01-16 2013-03-13 北卡罗来纳州大学 禽类物种中内源性原生殖细胞的耗减
WO2004066183A2 (en) * 2003-01-22 2004-08-05 European Molecular Biology Laboratory Microrna
US20040147027A1 (en) * 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
US20060247193A1 (en) 2003-02-10 2006-11-02 National Institute Of Advanced Industrial Science And Technology Regulation of gene expression by dna interference
US7816337B2 (en) 2003-02-18 2010-10-19 Roche Madison Inc. Reversible attachment of a membrane active polymer to a polynucleotide
US20040224337A1 (en) 2003-03-04 2004-11-11 Erik Foehr Use of biomolecular targets in the treatment and visualization of tumors
WO2004078941A2 (en) * 2003-03-06 2004-09-16 Oligo Engine, Inc. Modulation of gene expression using dna-rna hybrids
US20050112604A1 (en) 2003-03-14 2005-05-26 Akihide Fujimoto Loss of heterozygosity of the DNA markers in the 12q22-23 region
US7718364B2 (en) 2003-03-25 2010-05-18 John Wayne Cancer Institute DNA markers for management of cancer
US20040198640A1 (en) 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
EP1608733B1 (en) * 2003-04-02 2011-12-07 Dharmacon, Inc. Modified polynucleotides for use in rna interference
EP1608735A4 (en) 2003-04-03 2008-11-05 Alnylam Pharmaceuticals RNAI CONJUGATES
US20040229211A1 (en) 2003-05-13 2004-11-18 Yeung Wah Hin Alex Sensitive diagnostic testing methodology using multiplex real time PCR with one dye (MOD) and its use as in severe acute respiratory syndrome (SARS)
US7640114B2 (en) 2003-05-21 2009-12-29 The Wistar Institute Of Anatomy & Biology Method of diagnosis of cancer based on gene expression profiles in cells
ATE485394T1 (de) 2003-06-02 2010-11-15 Univ Massachusetts Verfahren und zusammensetzungen zur verbesserung der wirksamkeit und spezifität von fnai
US7750144B2 (en) 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
EP3502252B1 (en) 2003-06-02 2023-04-05 University of Massachusetts Methods and compositions for controlling efficacy of rna silencing
US20050059024A1 (en) 2003-07-25 2005-03-17 Ambion, Inc. Methods and compositions for isolating small RNA molecules
US7683036B2 (en) * 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US8106180B2 (en) * 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
US20050037362A1 (en) 2003-08-11 2005-02-17 Eppendorf Array Technologies, S.A. Detection and quantification of siRNA on microarrays
US20060183128A1 (en) 2003-08-12 2006-08-17 Epigenomics Ag Methods and compositions for differentiating tissues for cell types using epigenetic markers
WO2005017145A1 (ja) 2003-08-13 2005-02-24 Japan Biological Informatics Consortium 機能性ｒｎａが制御する被制御遺伝子の同定・予測方法及びその利用方法
AP2006003618A0 (en) 2003-11-10 2006-06-30 Noxxon Pharma Ag Nucleic acids specifically binding bioactive ghrelin
US20050130170A1 (en) 2003-12-16 2005-06-16 Jeanne Harvey Identification and verification of methylation marker sequences
US20050130172A1 (en) 2003-12-16 2005-06-16 Bayer Corporation Identification and verification of methylation marker sequences
EP2295604B1 (en) 2004-02-09 2015-04-08 Thomas Jefferson University Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features
AU2005214904B2 (en) 2004-02-13 2011-07-21 Rockefeller University Anti-microRNA oligonucleotide molecules
US20050182005A1 (en) 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
KR100522307B1 (ko) * 2004-02-19 2005-10-19 변영철 화장용브러시
US7402389B2 (en) 2004-02-24 2008-07-22 The Translational Genomics Research Institute (Tgen) Compositions and methods for prognosis of cancers
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
CA2561073C (en) * 2004-03-27 2014-01-14 The Arizona Board Of Regents On Behalf Of The University Of Arizona Composition and method for cancer treatment
US20060134639A1 (en) 2004-04-06 2006-06-22 Huffel Christophe V Method for the determination of cellular transcriptional regulation
US7365058B2 (en) * 2004-04-13 2008-04-29 The Rockefeller University MicroRNA and methods for inhibiting same
KR20070004957A (ko) * 2004-04-20 2007-01-09 제나코 바이오메디컬 프로덕츠, 인코포레이티드 ｎｃＲＮＡ 검출 방법
EP2500431A3 (en) 2004-05-04 2013-12-18 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for reducing viral genome amounts in a target cell
EP1784501B1 (en) * 2004-05-14 2015-11-18 Rosetta Genomics Ltd VIRAL AND VIRUS ASSOCIATED MicroRNAS AND USES THEREOF
WO2005116261A2 (en) 2004-05-24 2005-12-08 Albert Einstein College Of Medecine Of Yeshiva University Rna expression microarrays
US7575863B2 (en) 2004-05-28 2009-08-18 Applied Biosystems, Llc Methods, compositions, and kits comprising linker probes for quantifying polynucleotides
EP2065466B1 (en) * 2004-05-28 2014-07-09 Asuragen, Inc. Methods and compositions involving MicroRNA
US20050287539A1 (en) 2004-06-29 2005-12-29 Emmanuel Labourier Methods and compositions for preparing capped RNA
EP1828215A2 (en) 2004-07-21 2007-09-05 Alnylam Pharmaceuticals Inc. Oligonucleotides comprising a modified or non-natural nucleobase
WO2006020768A2 (en) 2004-08-10 2006-02-23 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides
DK1797183T3 (da) 2004-09-02 2012-10-01 Univ Yale Regulering af onkogener med mikrornas
US20060057595A1 (en) 2004-09-16 2006-03-16 Applera Corporation Compositions, methods, and kits for identifying and quantitating small RNA molecules
US7825229B2 (en) 2005-03-25 2010-11-02 Rosetta Genomics Ltd. Lung cancer-related nucleic acids
US7642348B2 (en) 2004-10-04 2010-01-05 Rosetta Genomics Ltd Prostate cancer-related nucleic acids
US20090186353A1 (en) 2004-10-04 2009-07-23 Rosetta Genomics Ltd. Cancer-related nucleic acids
US7592441B2 (en) 2004-10-04 2009-09-22 Rosetta Genomics Ltd Liver cancer-related nucleic acids
US20060134661A1 (en) 2004-10-12 2006-06-22 Richard Essner Treatment of cancer and compositions
US20060078894A1 (en) * 2004-10-12 2006-04-13 Winkler Matthew M Methods and compositions for analyzing nucleic acids
FR2877350B1 (fr) 2004-11-03 2010-08-27 Centre Nat Rech Scient IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE
EP2302052B1 (en) 2004-11-12 2015-01-07 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
US7074622B2 (en) * 2004-11-15 2006-07-11 Eastman Kodak Company Method and system for sorting and separating particles
JP2008521412A (ja) 2004-11-30 2008-06-26 ベリデックス・エルエルシー 肺癌予後判定手段
US20060154275A1 (en) 2004-12-02 2006-07-13 The Board Of Trustees Of The Leland Stanford Junior University Regulated genes in cervical cancer
US20060185027A1 (en) 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
EP1838870A2 (en) * 2004-12-29 2007-10-03 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs
AU2006211960A1 (en) * 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Compositions and methods involving MDA-7 for the treatment of cancer
US20090062184A1 (en) 2005-03-24 2009-03-05 Dainippon Sumitomo Pharma Co., Ltd. Fine particulate preparation comprising complex of nucleic acid molecule and collagen
US7495073B2 (en) * 2005-03-24 2009-02-24 Asia Hepato Gene Company Short isoform of Annexin A10 at chromosome 4q, termed Annexin 10s (ANXA10s) and methods of use
GB2425311A (en) * 2005-04-15 2006-10-25 Ist Superiore Sanita Micro RNA against kit protein
EP1874793A4 (en) 2005-04-15 2008-12-24 Univ Texas DISTRIBUTION OF SIRNA BY NEUTRAL LIPID COMPOSITIONS
AU2006242154B2 (en) 2005-05-02 2011-11-03 Cold Spring Harbor Laboratory Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
US20070072201A1 (en) * 2005-05-16 2007-03-29 Kohne David E Method for producing improved nucleic acid oligomer functional homogeneity and functional characteristic information and results and oligomer application results
US20060265771A1 (en) * 2005-05-17 2006-11-23 Lewis David L Monitoring microrna expression and function
GB0601102D0 (en) * 2006-01-19 2006-03-01 Nuclea Biomarkers Llc Kinase Peptides And Antibodies
US20070054287A1 (en) * 2005-05-31 2007-03-08 Applera Corporation Method for identifying medically important cell populations using micro rna as tissue specific biomarkers
WO2006128245A1 (en) 2005-06-03 2006-12-07 Southern Adelaide Health Service-Flinders Medical Centre Targeting cells with altered microrna expression
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling
EP1896602A4 (en) * 2005-06-09 2009-08-12 Epoch Biosciences Inc IMPROVED AMPLIFICATION PROCESSES ON PRIMER BASIS
US20060292616A1 (en) 2005-06-23 2006-12-28 U.S. Genomics, Inc. Single molecule miRNA-based disease diagnostic methods
KR101140575B1 (ko) * 2005-06-30 2012-05-02 엘지디스플레이 주식회사 액정표시장치 검사공정
CA2617581A1 (en) 2005-08-01 2007-02-08 The Ohio State University Research Foundation Microrna-based methods for the diagnosis of breast cancer
IL177006A0 (en) 2005-08-02 2006-12-10 Veridex Llc Predicting bone relapse of breast cancer
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20070041934A1 (en) 2005-08-12 2007-02-22 Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
WO2007033023A2 (en) 2005-09-12 2007-03-22 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of bcl2-associated cancers
AU2006311894A1 (en) 2005-11-04 2007-05-18 Merck Sharp & Dohme Corp. Method of treating cancers with SAHA and pemetrexed
US7390792B2 (en) 2005-12-15 2008-06-24 Board Of Regents, The University Of Texas System MicroRNA1 therapies
JP5713377B2 (ja) 2005-12-28 2015-05-07 ザ スクリプス リサーチ インスティテュート 薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
US20100286044A1 (en) 2005-12-29 2010-11-11 Exiqon A/S Detection of tissue origin of cancer
EP2468894B1 (en) 2006-01-05 2014-12-10 The Ohio State University Research Foundation MicroRNA-based Methods and Compositions for the Diagnosis of Breast Cancer
CN103361424A (zh) 2006-01-05 2013-10-23 俄亥俄州立大学研究基金会 胰腺内分泌和腺泡肿瘤中的微小rna表达异常
AU2007205234B2 (en) 2006-01-05 2012-07-12 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
US20070259827A1 (en) 2006-01-25 2007-11-08 University Of Massachusetts Compositions and methods for enhancing discriminatory RNA interference
WO2007090073A2 (en) 2006-01-27 2007-08-09 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
EP1991706B1 (en) 2006-03-02 2014-01-15 The Ohio State University Research Foundation Microrna expression profile associated with pancreatic cancer
US7955848B2 (en) 2006-04-03 2011-06-07 Trustees Of Dartmouth College MicroRNA biomarkers for human breast and lung cancer
EP2047864B1 (en) * 2006-06-16 2017-04-05 Taisho Pharmaceutical Co., Ltd. Use of rpn2 gene expression inhibitor
US20080076674A1 (en) * 2006-07-06 2008-03-27 Thomas Litman Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer
ES2425387T3 (es) 2006-07-13 2013-10-15 The Ohio State University Research Foundation Mir-106a para diagnosticar adenocarcinoma de colon de pronóstico de supervivencia pobre
WO2008014008A2 (en) 2006-07-28 2008-01-31 The Johns Hopkins University Compositions and methods for modulating angiogenesis
JP2010504350A (ja) 2006-09-19 2010-02-12 アシュラジェン インコーポレイテッド 治療的介入の標的としての、ｍｉＲ−２００によって調節される遺伝子および経路
CA2664383C (en) * 2006-09-19 2017-08-22 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
WO2008036776A2 (en) 2006-09-19 2008-03-27 Asuragen, Inc. Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
US20080131878A1 (en) * 2006-12-05 2008-06-05 Asuragen, Inc. Compositions and Methods for the Detection of Small RNA
CN101622349A (zh) * 2006-12-08 2010-01-06 奥斯瑞根公司 作为治疗性干预靶标的miR-21调节的基因和途径
CA2671294A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
CA2671299A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Functions and targets of let-7 micro rnas
CA2671194A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Mir-20 regulated genes and pathways as targets for therapeutic intervention
CA2671270A1 (en) 2006-12-29 2008-07-17 Asuragen, Inc. Mir-16 regulated genes and pathways as targets for therapeutic intervention
EP2111408A4 (en) 2007-01-17 2010-02-03 Univ Johns Hopkins COMPOSITIONS AND METHODS OF microRNA FOR THE TREATMENT OF NEOPLASIA
EP2124967A4 (en) 2007-01-26 2011-01-05 Rosetta Genomics Ltd COMPOSITIONS AND METHOD FOR THE TREATMENT OF HEMATOPOIETIC MALIGNOMES
WO2008095096A2 (en) 2007-01-31 2008-08-07 Immune Disease Institute Let-7 microrna and mimetics thereof as therapeutics for cancer
CN101680039B (zh) 2007-04-20 2016-08-24 希格马托罕见疾病有限公司 酶的抗癌治疗
CN101827941B (zh) 2007-04-30 2014-07-16 俄亥俄州立大学研究基金会 用于区分胰腺癌与正常胰腺功能和/或慢性胰腺炎的方法
WO2008137862A2 (en) * 2007-05-03 2008-11-13 Rosetta Inpharmatics Llc Methods of using mir34 as a biomarker for tp53 functional status
US20090232893A1 (en) 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090131354A1 (en) * 2007-05-22 2009-05-21 Bader Andreas G miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
CN101801419A (zh) 2007-06-08 2010-08-11 米尔纳疗法公司 作为治疗干预的靶标的miR-34调控的基因和路径
EP2198050A1 (en) 2007-09-14 2010-06-23 Asuragen, INC. Micrornas differentially expressed in cervical cancer and uses thereof
US7993831B2 (en) 2007-09-14 2011-08-09 Asuragen, Inc. Methods of normalization in microRNA detection assays
WO2009052386A1 (en) 2007-10-18 2009-04-23 Asuragen, Inc. Micrornas differentially expressed in lung diseases and uses thereof
WO2009058907A2 (en) 2007-10-29 2009-05-07 Isis Pharmaceuticals, Inc. Targeting micrornas for the treatment of liver cancer
WO2009070805A2 (en) * 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
US20110009469A1 (en) * 2007-12-05 2011-01-13 The Johns Hopkins University Compositions and methods of treating neoplasia
WO2009086156A2 (en) 2007-12-21 2009-07-09 Asuragen, Inc. Mir-10 regulated genes and pathways as targets for therapeutic intervention
WO2009100430A2 (en) 2008-02-08 2009-08-13 Asuragen, Inc miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
EP2096171A1 (en) * 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
US20110052502A1 (en) 2008-02-28 2011-03-03 The Ohio State University Research Foundation MicroRNA Signatures Associated with Human Chronic Lymphocytic Leukemia (CCL) and Uses Thereof
WO2009111643A2 (en) 2008-03-06 2009-09-11 Asuragen, Inc. Microrna markers for recurrence of colorectal cancer
WO2009109665A1 (en) * 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
WO2009154835A2 (en) 2008-03-26 2009-12-23 Asuragen, Inc. Compositions and methods related to mir-16 and therapy of prostate cancer
US20090258928A1 (en) 2008-04-08 2009-10-15 Asuragen, Inc. Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
WO2009137807A2 (en) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
CN102112110A (zh) 2008-06-06 2011-06-29 米尔纳医疗股份有限公司 用于RNAi试剂体内递送的新型组合物
US20100090959A1 (en) 2008-10-14 2010-04-15 Sony Ericsson Mobile Communications Ab Forming a keyboard from a combination of keys displayed on a touch sensitive display and on a separate keypad
WO2010056737A2 (en) 2008-11-11 2010-05-20 Mirna Therapeutics, Inc. Methods and compositions involving mirnas in cancer stem cells
US8492133B2 (en) * 2009-01-20 2013-07-23 Ramot At Tel Aviv University, Ltd. MIR-21 promoter driven targeted cancer therapy
US7665785B1 (en) 2009-04-08 2010-02-23 Newton Paul A Column pipe catch tool
US8778903B2 (en) * 2009-10-21 2014-07-15 Trustees Of Dartmouth College MicroRNA-10 antagonists and MicroRNA-10 targets for use in the treatment of a glioma
WO2011059752A1 (en) 2009-10-28 2011-05-19 Board Of Regents Of The University Of Texas System Methods and compositions for anti-egfr treatment
AU2010321555B2 (en) 2009-11-23 2015-10-15 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
WO2011063455A1 (en) 2009-11-24 2011-06-03 The University Of Western Australia Modulation of epidermal growth factor receptor ligands
WO2011088309A1 (en) 2010-01-14 2011-07-21 Regulus Therapeutics Inc. Microrna compositions and methods
WO2012041959A1 (en) 2010-09-30 2012-04-05 University Of Zurich Treatment of b-cell lymphoma with microrna
CA2826043A1 (en) * 2011-02-03 2012-08-09 Mirna Therapeutics, Inc. Synthetic mimics of mir-124
RU2615117C2 (ru) 2011-02-03 2017-04-04 Мирна Терапетикс, Инк. ДВУХЦЕПОЧЕЧНАЯ МОЛЕКУЛА РНК ДЛЯ ОБЕСПЕЧЕНИЯ КЛЕТКИ АКТИВНОСТЬЮ miR-34a
WO2012135728A1 (en) 2011-03-30 2012-10-04 University Of Louisville Research Foundation, Inc. Catalytic isomerisation of linear olefinic hydrocarbons
EP3933040A1 (en) 2011-04-25 2022-01-05 Sanofi Microrna compounds and methods for modulating mir-21 activity
AU2012347498A1 (en) 2011-12-10 2014-06-26 Ohio State Innovation Foundation MiRNAs useful to reduce lung cancer tumorigenesis and chemotherapy resistance and related compositons and methods
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
KR20150131312A (ko) 2013-03-15 2015-11-24 미르나 테라퓨틱스 인코포레이티드 마이크로rna 및 egfr-tki 억제제를 이용한 조합 암 치료
CA2914685A1 (en) 2013-06-24 2014-12-31 Mirna Therapeutics, Inc. Biomarkers of mir-34 activity
US20160136181A1 (en) 2014-04-01 2016-05-19 Mirna Therapeutics, Inc Microrna dosing regimens

Also Published As

Publication number Publication date
EP2322616A1 (en) 2011-05-18
EP2292756B1 (en) 2014-07-16
US20150004221A1 (en) 2015-01-01
US20150275213A1 (en) 2015-10-01
US20150005366A1 (en) 2015-01-01
AU2005333165A1 (en) 2006-12-28
JP2014217386A (ja) 2014-11-20
AU2005333165B2 (en) 2012-07-19
US20150284719A1 (en) 2015-10-08
CA2587189A1 (en) 2006-12-28
US8058250B2 (en) 2011-11-15
ES2534303T3 (es) 2015-04-21
EP2287303A1 (en) 2011-02-23
US20110313025A1 (en) 2011-12-22
ES2503743T3 (es) 2014-10-07
EP2314688A1 (en) 2011-04-27
US20130303591A1 (en) 2013-11-14
WO2006137941A2 (en) 2006-12-28
EP2281888A1 (en) 2011-02-09
US9506061B2 (en) 2016-11-29
EP2302051A1 (en) 2011-03-30
ES2534304T3 (es) 2015-04-21
EP2298894A1 (en) 2011-03-23
JP2012228254A (ja) 2012-11-22
EP2302052B1 (en) 2015-01-07
JP2014012020A (ja) 2014-01-23
US20120065248A1 (en) 2012-03-15
US20150361431A1 (en) 2015-12-17
US20150344881A1 (en) 2015-12-03
CA2850323A1 (en) 2006-12-28
US20150299705A1 (en) 2015-10-22
JP5596085B2 (ja) 2014-09-24
EP2284265B1 (en) 2015-01-07
WO2006137941A3 (en) 2008-01-03
US8173611B2 (en) 2012-05-08
EP2281886B1 (en) 2014-07-16
US8765709B2 (en) 2014-07-01
US8563708B2 (en) 2013-10-22
JP2014217385A (ja) 2014-11-20
EP2302051B1 (en) 2015-01-07
US7960359B2 (en) 2011-06-14
EP2808389A1 (en) 2014-12-03
EP2302055A1 (en) 2011-03-30
EP2298893A1 (en) 2011-03-23
EP2281889B1 (en) 2014-07-30
ES2503741T3 (es) 2014-10-07
US20150342981A1 (en) 2015-12-03
US20140031415A1 (en) 2014-01-30
EP2302054B1 (en) 2014-07-16
EP2284265A1 (en) 2011-02-16
CA2857880A1 (en) 2006-12-28
JP5389690B2 (ja) 2014-01-15
US20080176766A1 (en) 2008-07-24
EP2314688B1 (en) 2014-07-16
SI2302055T1 (sl) 2015-01-30
EP2298894B1 (en) 2014-07-16
CA2857881A1 (en) 2006-12-28
US9447414B2 (en) 2016-09-20
CA2857878A1 (en) 2006-12-28
ES2534301T3 (es) 2015-04-21
CA2857901A1 (en) 2006-12-28
US20150284720A1 (en) 2015-10-08
US20170037404A1 (en) 2017-02-09
US9068219B2 (en) 2015-06-30
JP2010178741A (ja) 2010-08-19
EP2302054A1 (en) 2011-03-30
ES2503742T3 (es) 2014-10-07
PL2302055T3 (pl) 2015-02-27
US20130143945A1 (en) 2013-06-06
US20090176723A1 (en) 2009-07-09
JP5620556B2 (ja) 2014-11-05
ES2534300T3 (es) 2015-04-21
WO2006137941A9 (en) 2007-03-08
EP2302056A1 (en) 2011-03-30
JP2008519606A (ja) 2008-06-12
ES2507544T3 (es) 2014-10-15
EP2281886A1 (en) 2011-02-09
ES2503740T3 (es) 2014-10-07
ES2534302T3 (es) 2015-04-21
EP2281887A1 (en) 2011-02-09
US20140348908A1 (en) 2014-11-27
EP2281888B1 (en) 2015-01-07
US20140314833A1 (en) 2014-10-23
EP2292755A1 (en) 2011-03-09
US8946177B2 (en) 2015-02-03
US20080050744A1 (en) 2008-02-28
JP2014223080A (ja) 2014-12-04
ES2503765T3 (es) 2014-10-07
EP2808390A1 (en) 2014-12-03
EP2292756A1 (en) 2011-03-09
EP2302053A1 (en) 2011-03-30
US9382537B2 (en) 2016-07-05
ES2503738T3 (es) 2014-10-07
ES2503739T3 (es) 2014-10-07
JP2014217384A (ja) 2014-11-20
EP2281889A1 (en) 2011-02-09
CA2857879A1 (en) 2006-12-28
EP2302056B1 (en) 2015-01-07
US9051571B2 (en) 2015-06-09
JP2014217387A (ja) 2014-11-20
EP2287303B1 (en) 2014-07-02
EP2302052A1 (en) 2011-03-30
EP1838852A2 (en) 2007-10-03
JP2014217381A (ja) 2014-11-20
EP2302055B1 (en) 2014-08-27
DK2302055T3 (da) 2014-10-13
US20080171715A1 (en) 2008-07-17
US20140348907A1 (en) 2014-11-27
US20140350086A1 (en) 2014-11-27
JP2016165292A (ja) 2016-09-15
US20150352046A1 (en) 2015-12-10
US20150344883A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
HK1204656A1 (en) Methods and compositions involving mirna and mirna inhibitor molecules mirna mirna
EP2010676A4 (en) METHOD AND KIT FOR MOLECULAR QUANTIFICATION OF CHROMOSOMES
EP2035014A4 (en) FUCOIDANE PREPARATIONS AND METHODS
PT2101766T (pt) Composições e métodos de utilização de (r)-pramipexole
EP1895838A4 (en) COMPOSITIONS AND METHODS
GB0604973D0 (en) Purification method and kit
GB0522287D0 (en) Method and compositions
EP2101731A4 (en) PROCESSES AND COMPOSITIONS WITH END OXIFES
HK1223968A1 (zh) 狂犬病病毒組合物和方法
GB0603295D0 (en) Methods and kits
PL2101766T3 (pl) Kompozycje i sposoby stosowania (R)-pramipeksolu
HK1137756A1 (en) Substituted dihydropyrazolones and use thereof as hif-prolyl-4 -hydroxylase inhibitors hif--4-
IL247957A0 (en) Anti-ephrinb2 antibodies and methods of using them
GB0525314D0 (en) Method and composition
GB0617171D0 (en) Novel compositions and methods
PL2132251T3 (pl) Kompozycja i sposób
ZA200802969B (en) Composition and method
GB0625208D0 (en) Composition and method
GB0524927D0 (en) Compositions and method
EP1807512A4 (en) COMPOSITIONS AND METHODS FOR REVERSE TRANSCRIPTION
GB0600261D0 (en) Composition and method
GB0522655D0 (en) Composition and method
GB0511235D0 (en) Compositions and method
GB0501348D0 (en) Compositions and methods
GB0604315D0 (en) Composition and method